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Abstract
Successful immune reconstitution decreases morbidity and mortality following 
human bone marrow transplantation (BMT). Unmanipulated haploidentical BMT 
followed by post-transplant cyclophosphamide (pt-Cy) has recently been introduced 
not only to provide a donor for nearly all patients lacking an HLA-matched donor, 
but also to improve immune competence through the transfer of adaptive immune 
cells with the graft. However, the mechanisms of reconstitution and the Cy-effect 
on transferred immune cells remain unknown. Here, we investigated the dynamics 
of B and T cell reconstitution in this setting and provide evidence that they follow 
two different mechanisms. Adoptively-transferred mature B cells fail to persist in the 
recipient and the recovering B cells derive from a de novo differentiation process 
from haematopoietic stem cells or B cell precursors. They display an 
immature/transitional phenotype in the early weeks post-transplant and then 
progress through four differentiation stages identified by CD5 and CD21 expression, 
including a novel CD5XD21" stage of transitional differentiation. Mature, naYve B 
cells later replace transitional cells and predominate in the B cell compartment for 6 
months. In contrast, transferred naive T cells (Tn) preferentially survive Cy 
compared to memory cells. T N rapidly differentiate into T memory stem cells 
endowed with superior reconstitution capacity within days post-infusion and later 
contribute to peripheral reconstitution by differentiating into effectors. Similarly, 
pathogen-specific memory T cells generated detectable recall responses but only 
in the presence of the cognate antigen. Therefore, T cell immunity is at least in part 
preserved following pt-Cy and may act as a first line of defence against reactivating 
pathogens and residual tumor cells. Differently, B cell immunity is generated de 
novo and takes at least 6 months to phenotypically resemble that of healthy donors.
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Overall, these findings define the cellular basis of adaptive immune 
reconstitution process and shed light on basic aspects of T and B cell differentiation 
and persistence.
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1 Introduction
1.1 Bone marrow and haematopoietic cell 
transplantation
Bone marrow transplantation (BMT) and haematopoietic stem cell 
transplantation (HSCT), following either marrow-ablative or non-myeloablative 
conditioning regimen, are widely used for the treatment of a variety of 
hematological malignancies including lymphoma, acute and chronic leukemias, 
multiple myeloma, myelodysplastic syndrome and myeloproliferative disorders1.
This therapy comprises the administration of a transplantation conditioning regimen, 
which consists of high-dose chemotherapy with or without total body irradiation, 
followed by the intravenous transfusion of marrow or peripheral blood (PB) stem 
cells from the donor. Human leukocyte antigen (HLA)-matched sibling donors are 
generally chosen for these procedures because they are best associated with 
overall and progression-free survival2. However, donor availability represents a 
major problem as only about one-third of candidates for allogeneic BMT (allo-BMT) 
have HLA-matched siblings3. When HLA-matched siblings donors are not available, 
there are three possible source of haematopoietic stem cells: HLA-matched 
unrelated donors (who are not always identified in the international registries), 
umbilical cord blood and partially HLA-mismatched, haploidentical, related donors, 
who have one HLA haplotype in common with the recipient4. Haploidentical donors 
can be identified rapidly in nearly all cases because the patient shares one HLA 
haplotype with each biological parent or child and half of his/her siblings. However, 
graft rejection and graft-versus-host disease (GVHD) remain the major 
complications of HLA-haploidentical BMT (haploBMT)5-8. These are both 
consequences of the diversity in the histocompatibility complex antigens9 and result
from the excessive alloreactivity of host T cells10, in the case of graft rejection, and 
of donor T cells11, in the case of GVHD.
Ex-vivo T cell depletion, which removes T cells from the donor graft, may be 
employed to prevent GVHD without the morbidity associated with 
immunosuppressive drugs12'16. This procedure significantly reduces the incidence 
and severity of GVHD, but does not improve overall survival. Indeed, donor T cells 
in the recipient play a major role in the prevention of infections and mediate 
malignancy eradication (graft-versus-tumor effect)17. Thus, the absence of donor T 
cells in the graft is associated with disease relapse and a high risk of serious 
infection and death due to prolonged immune deficiency in the recipients18'23. For 
these reasons, other methods are required to selectively inhibit alloreactivity, while 
preserving immunity against pathogens and tumor cells.
1.2 Unmanipulated HLA haploBMT with high dose 
cyclophosphamide
A non-myeloablative conditioning regimen followed by non-T cell-depleted 
(unmanipulated) BMT from an HLA-haploidentical donor has recently been 
proposed in patients with poor risk hematological malignancies and non-malignant 
hematological disorders3,24*27. The key feature of this clinical protocol, first applied 
by a group from Baltimore3,24,25, is the employment of high dose, post-transplant 
cyclophosphamide (pt-Cy) given to prevent GVHD. According to studies in mice28, 
Cy selectively depletes alloreactive T cells in vivo after infusion of unmanipulated 
grafts and spares bystander naive and memory T cells3,25,29.
Cy is a highly immunosuppressive antineoplastic agent that has been 
employed since the 1960s to modulate the allograft response30. It causes apoptosis 
in proliferating cells and, in the allo-BMT context, would be expected to deplete
allogeneic antigen-stimulated cells and cause clonal deletion. Typically, the drug 
was administered before transplantation to prevent graft rejection by suppressing 
the host immune system. However, it has been demonstrated that pre­
transplantation conditioning regimen with Cy increases the risk of GVHD following 
allogeneic T cell infusion in mouse models31. On the other hand, the administration 
of a properly timed, high dose of Cy after BMT inhibited both graft rejection and 
GVHD28,32'34.
Given that T cells undergoing replicative DNA synthesis are uniquely 
sensitive to Cy, both anti-host and anti-donor T cells are selectively destroyed29. In 
the non-T cell-depleted haploBMT protocol used by the Baltimore group, allogeneic 
T cells are activated quickly after transfer and are therefore depleted by the 
administration of Cy25,29. Non-allogeneic T cells are spared and can subsequently 
mediate immune reconstitution in response to the lymphopenic environment of the 
patient.
The Baltimore group protocol gives good results in terms of clinical outcome: 
engraftment occurs rather rapidly and non-relapse mortality, acute and chronic 
GVHD and survival are comparable to other studies where reduced conditioning 
regimen and HLA-haploidentical donors were employed3,35. The most important 
result, however, was that serious opportunistic infections were diminished. Indeed, 
deaths from infection were low despite the incidence of reactivation25,26,29,36. 
Using the same clinical protocol, Raiola et al. reported that the incidence of 
cytomegalovirus (CMV) reactivation was 42% and that EBV DNAemia was 
detected in 23% of patients. However, no patient died of CMV disease, invasive 
fungal infection or sepsis and no post-transplant EBV-associated 
lymphoproliferative disorders were observed26, suggesting effective immune 
reconstitution in these patients.
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1.3 Immune reconstitution after haploBMT
The immune reconstitution process dictates clinical outcome in patients who 
receive transplantation. Independently of the clinical protocol, all patients 
undergoing BMT inevitably experience ablation of the immune system following 
high-dose chemotherapy administered before transplantation. Conditioning of the 
patients, depending on its intensity, ablates or strongly constricts host 
haematopoiesis to suppress the patient’s immune system, with the aim of 
preventing graft rejection. As a consequence, the transplant preparative regimen 
results in a severe and protracted lymphopenia, which is followed by the immune 
reconstitution phase.
Recovery of a fully functional immune system is a slow process following 
allogeneic stem cell transplantation and its duration differs between the various 
immune cell populations. The innate immune system, which includes neutrophils, 
monocytes, dendritic cells (DCs), macrophages and natural killer (NK) cells, 
normalizes rapidly compared to the adaptive immune system37. It is documented 
that neutrophils reconstitute at a median of approximately 15 days after 
unmanipulated haploBMT3, whereas NK cells circulate at normal levels by 1 month 
post-transplant38*43. In contrast, DCs recovery is delayed and lies chronologically 
between innate and adaptive immune recovery40,41,44*51. While innate immunity 
reconstitutes quickly, adaptive B and T cell recovery is delayed for years following 
transplantation, resulting in a global immune deficiency37. The following section will 
be focused on adaptive immune cells and will describe the T and B cell 
compartments and their immune reconstitution process.
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1.4 Adaptive immunity: T cell compartment
T lymphocytes belong to the adaptive arm of the immune system. They derive 
from progenitors that arise from multipotent haematopoietic stem cells in the bone 
marrow (BM) and subsequently migrate to the thymus to undergo a process of 
maturation that includes the rearrangement of the T cell receptor (TCR) genes. 
TCRs mediate the antigen recognition throught interactions with linear peptides 
presented by MHC molecules on the surface of antigen-presenting cells (APCs) or 
target cells52. TCR consists of a variable TCRap heterodimer that forms a 
multimeric receptor complex with the CD3 complex, which exists as a series of 
dimers including ys, be, and g  associated with a single ap heterodimer53,54. The 
binding of TCRap with complexes of peptide and MHC molecules results in 
biochemical changes in the cytoplasmic portions of the CD3 complex like the 
phosphorylation of the tyrosine-based activation motifs (ITAMs) by the Src family 
tyrosine kinases LCK and FYN, essential for TCR signalling55.
TCR ap heterodimers are generated during thymic development: thymocytes 
recombine variable (V), diversity (D) and joining (J) segments of the locus encoding 
TCR p, and V and J segments of the locus encoding TCRa, to form functional 
receptors. Diversity is further increased through the addition and subtraction of 
nucleotides at the gene segment junctions56,57. This method of generating receptor 
diversity provides TCR repertoire which contains an estimated 2.5 * 108 different 
TCRs in the periphery of humans58, which enables highly specific immune 
responses to a diverse range of foreign antigens52.
TCR rearrangements is followed by the so-called positive and negative 
selection59. Positive selection is the process through which the thymocytes become 
restricted by the host major histocompatibility complex (MHC): only thymocytes 
able to bind the host MHC with sufficient affinity, able to initiate an immune
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response, will survive and will be released in the periphery59. In contrast, the 
process of negative selection deletes thymocytes that recognize self peptides in the 
context of host MHC molecules with high affinity. This mechanism ensures that 
only thymocytes recognizing non-self peptides are released in the periphery. It is 
estimated that 75% of thymocytes are eliminated by negative selection in the 
thymus60. Post-thymus mature T cells, called naYve T cells (Tn), retain low levels of 
self-reactivity that are insufficient to induce autoimmunity, but essential for survival, 
as the interaction with self peptide-MHC (pMHC) complexes regulates their 
homeostasis61,62.
T n leave the thymus and migrate through the blood and lymph to secondary 
lymphoid tissues, i.e. the spleen and lymph nodes, where they continuously scan 
APCs in search of cognate non-self antigens63. If cognate antigen is encountered, 
Tn undergo a process of activation characterized by extensive proliferation (clonal 
expansion) and acquisition of effector functions that are necessary to eliminate 
infected cells64. When the pathogen is cleared, about 95% of T cells die, but a 
small fraction survives, giving rise to a long-lived population termed memory T cells 
(T mem)65- These cells are clonally expanded and ensure more rapid recall activation 
than naYve cells, thus providing protection following re-infection.
1.4.1 Heterogeneity of the T cell population
The memory compartment comprises T cell subsets that differ in terms of
phenotypic composition, functional activity and capacity to respond to homeostatic 
or antigenic simulation66. Indeed, the T cell compartment is highly heterogeneous. 
In 1999, Sallusto and Lanzavecchia reported that antigen-experienced CD4+ and 
CD8+ T cells can be divided into two main subsets, termed central memory (TCm) 
and effector memory (TEm), on the basis of their migratory capacity in the body. The
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more differentiated TEm preferentially migrate to peripheral tissues and show 
immediately effector capacities in response to antigen re-exposure66. On the other 
hand, the less differentiated TCm localize to secondary lymphoid organs and show 
little effector functions, although they have a high capacity to proliferate and 
differentiate into effector cells in response to antigen stimulation67'69.
T cm  are thought to maintain long-term memory in a stem cell-like fashion. 
Recently, studies in mice and later in humans and rhesus macaque, identified a 
new memory T cell population, termed T stem cell memory (T s c m )70’72. These cells, 
which represent the 2-3% of all circulating CD4+ and CD8+ human T cells, exhibit 
features between naTve and memory cells71. Indeed, T scm  display a largely Tn-like 
phenotype, retain a core of genes expressed by TN and, similar to TN, have a 
tropism for secondary lymphoid tissues71'73. Conversely, T scm  have low TREC 
content and have functional capacities of conventional memory T cells: like Tcm and 
T e m . T scm  undergo proliferation in response to interleukin (IL)-15 and, upon 
superantigen stimulation, rapidly acquire effector functions producing IL-2, TNF-a 
and interferon (IFN)-y71. Collectively, these data demonstrate that T scm  constitute 
an intermediate population between naTve and memory cells, and represent the 
earliest differentiated memory T cell population in humans71*73.
T scm  also retain stem cell-like qualities, including a higher capacity to self- 
renew in vitro and to generate more differentiated progeny compared to T c m 71,73. 
Indeed, after anti-CD3/CD2/CD28 stimulation, which induces T cell differentiation, 
T scm  demonstrate a twofold higher capacity to maintain the original phenotype 
when compared with TcM71rMoreover, T scm  display greater multipotency compared 
to all the other memory cells as demonstrated by their ability to generate all other 
memory subsets, including T cm71,73-
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Between T Cm and T Em, further T cell subset has been characterized, termed 
transitional memory (TTm)74’75, which appears to be more differentiated than TCm but 
not as fully differentiated as T Em in terms of phenotype76,77 and magnitude of 
expansion in response to IL-1578,79. In addition, a T terminal effector (Tte ) subset 
comprises the most differentiated T cells74,75. They have low proliferative and 
functional capacity75,80,81, tend to undergo apoptosis and have the shortest 
telomeres among T cells82, thus indicating terminal differentiation74,75.
These observations suggest that memory T cell differentiation in humans 
progresses linearly according to the relationship Tn~> Tscm-^Tcm->Ttm->TEm->TtE 
71,74,75 (pjgure |n thjs model, T cells lose some abilities, such as the capacity to 
migrate to secondary lymphoid tissues, multipotency and self-renewal (i.e., the 
capacity to persist in the body), but gain others, such as effector functions and 
tropism for peripheral tissues71'73.
Naive
T n Antigen experienced T cells
CD45RA+ CD45RA+ CD45RA-
CD45RO- CD45RO- CD45RO
CCR7+ CCR7+ CCR7+
CD28+ CD28+ CD28+
CD27+ CD27+ CD27+
IL-7R«+ IL-7Ra+ IL-7Ra+
CD95- CD95+ CD95+
CD57- CD57- CD57-
Proliferation
Sternness
Lymphoid homing
Lipid metabolism
Immune-reconstitution capacity
CD45RA- CD45RA" CD45RA
CD45RO+ CD45RO+ CD45RO
CCR7- CCR7- CCR7-
CD28+ CD28- CD28-
CD27+ CD27- CD27-
IL-7Ra+/~ IL-7Ra- IL-7Ra-
CD95+ CD95+ CD95+
CD57- CD57+/- CD57+
Cytotoxic activity 
Tissue tropism 
Senescence 
Glycolysis
Figure 1: T cell differentiation process, functions and phenotypic features of T cell 
subsets. Polychromatic flow cytometry analysis allows the identification of each T subset in the 
T cell compartment. Each T subset is characterized by the expression of specific markers. In
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red, the markers that change during differentiation from the previous subset. Going from less 
differentiated T cells to more differentiated ones, functional abilities also change. Modified from 
Mahnke et al., Eur J Immunol, 201375.
Each T cell subset can be distinguished phenotypically by the expression of 
surface molecules, as revealed by flow cytometry72,83 (Figure 1). These markers 
include molecules involved in T cell activation, such as the splicing variants of the 
tyrosine phosphatase CD45R, the long isoform (CD45RA) and shortest isoform 
(CD45RO). The former isoform is characteristic of less differentiated T cells (TN and 
T s c m ), while the latter is expressed on more differentiated T cells ( T c m , T Tm , T e m ) 
with the exception of T i e . T i e , which are more frequent in the CD8+ than in the 
CD4+ T compartment, are able to re-express the naive marker CD45RA, although 
they are distinguished from Tn by the absence of other naYve markers (e.g. CC 
chemokine receptor (CCR)-7, CD27, CD28 and IL7Ra), the expression of 
senescence markers (e.g. the killer cell lectin-like receptor -1 (KLRG-1)84 and CD57, 
a marker of terminal differentiation80) and the phosphorylation of histone 
H2AX72,85,86. Among the markers expressed by memory T cells, CD95 is essential 
to distinguish T scm  from T n : it is expressed on T scm  but not on T n71*73.
Other markers involved in the co-stimulation and survival of T cells, which 
permit the discrimination of specific T subsets, include the TNF receptor 
superfamily member CD27 and CD28, the receptor for CD80 and CD86. The 
expression of the molecules is down-regulated in the late stages of differentiation 
( T e m , T i e ) . Homing receptors also have an important role in the identification of 
subsets with different capabilities to localize to peripheral tissue: CCR7 and the cell 
adhesion molecule L-selectin (CD62L), both necessary for homing to high 
endothelial venules in the lymph nodes, are expressed at high levels in j N66 67-72-74.
In contrast, memory cells are split into CCR7+CD62L+ (T sc m  and T c m )  and CCR7' 
C D 6 2 L ‘ (T t m , T em  and T i e ). In contrast to CCR7 and CD62L, the expression of
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CCR5 and the chemokine (C-X-C motif) receptor 3 (CXCR3), which allow migration 
to inflamed tissues, are increased on more differentiated T cells ( T c m , T tm , T Em ) but 
largely absent on TN and T s c m -
T cells subsets respond differently to cytokines due to the differential 
expression of cytokine receptors. Among them, CD127, the a-chain of the IL-7 
receptor (IL-7Ra), and CD 122, the p chain of the IL-2/IL-15 receptor complex, have 
important roles in T cell development and homeostasis72. CD127 is prevalently 
expressed on less differentiated cells, which are more sensitive to IL-7. In contrast, 
more differentiated cells express CD122 and respond better to IL-1566-67-72-74_
Despite the high number of markers differentially expressed by T cell subsets, 
a minimal set of 4 markers can be used to identify unequivocally T n , T s c m , T c m , T t m , 
T em  and T Te within the CD4+ and in CD8+ T cell compartments: CD45RO, CD95, 
CCR7 and CD27. Additional markers are redundant and do not provide additional 
benefits in the identification of such cells72.
The following section describes the functions and homeostatic properties of 
the different T cell subsets.
1.4.2 Homeostasis of human T cells
It is well known that the number of T lymphocytes in the body is tightly
controlled by a mechanism called homeostatic proliferation87, which ensures a slow 
turnover in the absence of cognate antigen stimulation88. The maintenance and 
homeostatic proliferation of T cells is regulated by complex mechanisms which 
involve contacts with both self-pMHC and members of the common gamma chain 
(yc) cytokines, such as IL-2, IL-4 and, especially, IL-7 and IL-1561,89.
The important role of TCR-self-pMHC interactions for the maintenance of 
homeostasis was observed about 10 years ago. The lifespan of naive CD4+ and 
CD8+ T cells was shortened when these cells were deprived of contact with self-
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pMHC62, thus suggesting that self-pMHC complexes are crucial for maintaining the 
peripheral T cell pool. Indeed, in MHC class I or class II deficient mice, respectively 
CD8+ and CD4+ Tn were not able to survive90’96. However, the above-mentioned 
studies were performed in lymphopenic mouse models. Using non-lymphopenic 
model systems, other research groups found normal maintenance of CD4+ T 
cells61,87,91,97. Therefore, the effect of homeostatic stimuli differs when the 
physiological environment changes. However, irrespective of lymphopenic or 
normal physiological conditions, it was observed that self-pMHC had an important 
role in T n homeostasis and, in particular, T n, compared to memory cells, are more 
dependent on self-pMHC to undergo homeostatic proliferation61,98. The homeostatic 
proliferation of memory CD4+ and CD8+ cells is largely MHC-independent".
Memory CD8+ and CD4+ T cells persist indefinitely in MHCI^' or MHCII'7’ mice, 
respectively, and retain effector functions upon antigen re-encounter.
Despite the controversial data about the role of self-pMHC interactions in 
homeostatic proliferation, researchers agree that cytokines have an important role 
in this regard. Both naTve and memory cells need common yc cytokine signals to 
undergo homeostatic proliferation, despite differences between naTve and memory 
cells as regards reliance on these signals61. NaTve cells are more dependent on IL- 
7 compared to the other subsets to survive and proliferate61.
IL-7 is a cytokine produced by non-haematopoietic stromal and epithelial cells 
of the BM and thymus during lymphopoiesis as well as by non-haematopoietic and 
stromal cells of secondary lymphoid tissues, liver and intestine100. T cells respond 
to IL-7 through the IL-7R. This receptor is composed of 2 subunits: the common yc 
CD132, which is shared with the IL-2, IL-4, IL-9 and IL-15 receptors, and the a- 
chain (CD127), which confers cytokine specificity. CD 127 is expressed by naTve 
and memory T cells, but is down-regulated in terminally-differentiated memory cells
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(Tem and T t e ) 10\  as depicted in Figure 1. Its essential role was discovered several 
years ago by the finding that abrogation of contact with IL-7, either by adoptive 
transfer of T cells into IL-7 deficient hosts or by injection of an IL-7 blocking 
antibody into normal mice, reduced the survival of T n89. Additional experiments 
showed that overexpression of IL-7 in mice increased the size of the TN pool102.
In lymphopenic conditions, the availability of IL-7 increases because of 
diminished usage by T cells. Increased concentrations of IL-7 induce a potent 
downstream signal that amplifies the TCR signalling resulting from contact with 
self-pMHC ligands103. In this context, Tn proliferation is accompanied by the 
gradual differentiation in memory cells103. IL-7-induced TN proliferation is dampened 
by the presence of memory T cells, which compete for IL-7 signals104.
In lymphopenic conditions, other cytokines have a role in the proliferation of 
Tn, in particular IL-15 and IL-2. These cytokines are structurally and functionally 
related and share two of their three receptor chains, the IL-2/15 Rp (CD122) and 
the common y chain (CD132).
IL-15 is produced primarily by DCs, monocytes and epithelial cells in the 
presence of inflammatory signals105. It was initially characterized as a soluble 
molecule. Later it was shown that IL-15 also exists as a membrane-bound form, 
which is the prevalent form in vivo. In the membrane-bound form, IL-15 is 
complexed with high affinity to the a chain of its receptor (IL-15Ra) and binds target 
cells according to a mechanism known as trans-presentation81. If non-complexed 
with IL-15Ra, IL-15 is also able to bind to the 15Rpy signalling complex with 
intermediate affinity106.
Because IL-2 and IL-15 share receptor subunits (CD122 and CD132), both 
these cytokines have several shared downstream effects107, including induction of 
the anti-apoptotic molecule Bcl-2, activation of the mitogen-activated protein kinase
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(MAPK) pathway and phosphorylation of lymphocyte-activated protein tyrosine 
kinase (Lck) and spleen tyrosine kinase (Syk), which lead to cell proliferation and 
maturation106. However, these cytokines are not functionally redundant107. Mice 
deficient in IL-2 or IL-15 have different phenotypes, and administration of IL-2 and 
IL-15 to mice and primates leads to distinct immunological outcomes108,109.
Although both cytokines stimulate lymphocytes, IL-2 favours the homeostasis of 
regulatory T cells and regulates the differentiation of helper T cells110, whereas IL- 
15 favours the expansion of CD8+ memory cells108.
The important role of IL-15 was demonstrated in studies where memory cells 
were transferred in IL-15 deficient mice. In these hosts, memory cells failed to 
undergo homeostatic proliferation and died rapidly111. The increased expression of 
IL-15Ra and IL-2/15Rp-chain on more differentiated T cells (Figure 1) further 
indicates that IL-15 plays an important role in the homeostatic proliferation of 
memory cells rather than of naTve cells81.
To evaluate the role of cytokine stimulation on T cell subsets, Geginat and 
coworkers evaluated, in vitro, the acquisition of some phenotypic and functional 
features of purified T subsets isolated from human peripheral blood mononuclear 
cells (PBMCs). They compared cytokine and antigenic stimulation. The latter was 
provided by mature allogeneic DCs, whereas cytokine stimulation was provided 
mainly by IL-7, IL-15 and IL-281. In the absence of antigen stimulation, the response 
to IL-7 is comparable and low in all subsets. In contrast, the response to IL-15 
increases with progressive differentiation and the response to cytokine stimulation 
is boosted when IL-7 is added to the culture. Moreover, IL-2 selectively stimulates 
memory T cells and boosts responses to IL-7 and IL-1581. In regard to antigenic 
stimulation, T cm  and T em  show a higher sensitivity compared to T n and are less
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dependent on co-stimulation. In particular, Tcm produce mainly IL-267,112, whereas 
T em mainly produce IFN-y and are endowed with cytolytic capacity81,113.
Observing the cell phenotype after antigen and cytokine stimulation, T N, T c m , 
T em  and T te  give rise to a rather homogeneous population of CCR7" CD45RA" 
effector T cells. In contrast, after cytokine stimulation, all subsets are able to 
generate more differentiated cells in different combinations, while a fraction 
maintains the original phenotype, thus indicating the capacity to self-renew. These 
results suggest that both antigenic and cytokine stimulation induce the proliferation 
and differentiation of each subset to more differentiated T cells81. Among T cell 
subsets, T scm  self-renew and generate more differentiated progeny at a higher 
efficiency compared to T cm  in response to TCR stimulation (via a-CD3/CD2/CD28 
exposure) and homeostatic signals (via IL-15 stimulation)71. Following IL-15 
stimulation, about 60% of T scm  maintain their phenotypic markers compared to 
30% of T c m - After a-CD3/CD2/CD28 exposure, a fraction of T Scm  gradually up- 
regulates the memory marker CD45RO while down-regulating CD62L and CCR7 
over several divisions, giving rise to T cm  and T e m - Conversely, T cm  are able to 
maintain their original phenotype only in a smaller fraction compared to T Scm  and 
could only generate T em  but not T s c m , thus indicating that, at least in vitro, “de­
differentiation” does not occur71.
1.4.3 T cell recovery following immune ablation
As reported in previous sections, transient T cell immunodeficiency is the
inevitable consequence of high-dose chemotherapy for blood and solid cancers. 
Following immune ablation, the body attempts to restore the T cell compartment 
but the recovery of T cell populations is delayed compared to that of myeloid, NK or 
B cells114.
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Several studies have reported that T cell function is often compromised, even 
after normal lymphocyte numbers have recovered115*117, thus leading to serious 
clinical consequences, including a limited response to vaccines, reduced resistance 
to infection, tumor relapse and the development of autoimmunity116*119. T cell 
immune reconstitution is generally dependent on the contribution of two primary 
pathways: the generation of new T cells from progenitors via thymopoiesis 
(“thymic-dependent")120*122 and the peripheral expansion of residual mature 
lymphocytes by antigenic, allogeneic or cytokine-driven stimulation121,122.
The peripheral expansion pathway characterizes the early phase of immune 
reconstitution (up to 1 year post-transplantation): the T cells that survived 
chemotherapy or were adoptively transferred via BMT undergo vigorous expansion 
in response to increased homeostatic signals, namely those induced by IL-7 and 
IL-15, or stimulation by exogenous antigens121,123. The “thymic-dependent” phase 
occurs several months post-BMT and is characterized by the slow recovery of T 
cell lymphopoiesis leading to the production of new T n124.
The relative contribution of each pathway depends on host age (indeed, 
thymic activity decreases with age), residual T cells, homeostatic cytokine levels 
and endogenous antigenic stimulation122. Each pathway contributes to generate a 
different TCR repertoire of T cells: a more diverse repertoire through thymopoiesis 
and homeostatic expansion and an oligoclonal repertoire through antigen 
stimulation121,122. As indicated above, the CD4+ and CD8+ T cell compartments are 
highly heterogeneous and comprise subsets that respond differently to the 
mechanisms driving the reconstitution process. A clear understanding of the 
mechanisms that govern immune reconstitution is therefore important to predict T 
cell functionality after lymphopenia. However, a comprehensive analysis of T cell
21
subset immune reconstitution has never been reported, especially in the setting of 
haploidentical donors and reduced conditioning regimen.
1.5 Adaptive immunity: B cell compartment
Like T cells, B cells belong to the adaptive arm of the immune system. They 
are characterized by immunoglobulin (Ig) receptors that are involved in the 
recognition of intact antigen in its native form 125. Igs are generated by somatic 
recombination, whereby germline genes are re-arranged to create diverse receptor 
sequences.
1.5.1 Homeostasis and maturation of human B cells
Human B lymphocytes differentiate in the BM from common lymphoid
progenitors.126 Pre-B cells arise from progenitor (pro-B) cells that express neither 
the pre-B-cell receptor (pre-BCR) nor surface Ig. Early B cell development is 
characterized by the functional rearrangement of the Ig loci which culminates in the 
development of a diverse repertoire of functional Ig heavy and Ig light chain loci via 
V(D)J rearrangement127. The generated heavy and light chains constitute the B-cell 
receptor (BCR), whose expression is a requisite for B-cell development and allows 
survival and re-circulation in the periphery 128 127.
The recent BM emigrants, called transitional B lymphocytes, are 
characterized by the expression of CD38, CD10, CD24 and IgD129,130. These 
immature B cells exit the BM and mature stepwise in the periphery, a process that 
can be distinguished on the basis of multiple phenotypic markers: CD5129,131, 
CD21132, CD24, CD38 or CD10133,134. While progressing from the most immature 
CD21 -CD5+CD38bri9htCD24brightCD 10+ transitional T1 cells to 
CD21 +CD5+CD38dimCD24dim CD10+ T2 and CD21+CD5"CD10” naive cells129’130, B
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cells acquire proliferative and survival capacity and the potential to produce 
antibodies as well as undergo Ig class switching132.
Mature naive B cells migrate to secondary lymphoid structures. Once B cells 
encounter cognate antigen, often through interactions with CD4+ T cells or DCs, 
they become activated, undergo clonal expansion135 and release IgM. During clonal 
expansion, B cells may undergo isotype switching such that they express IgG, IgA 
or IgE on their cell surface. Moreover, somatic hypermutation, which consists of 
DNA mutations in the variable regions, may occur to increase the avidity of the 
antibody/epitope interaction37. These cells are the antigen-experienced B cells, 
which can leave the lymph node and migrate to the PB or lymphoid tissues136. B 
cell proliferation upon antigen encounter and T cell help is a key step in the 
humoral immune response137,138.
In addition to the classical B cell maturation process, another T-independent 
mechanism has been extensively described. Indeed, transitional B cells may also 
mature as marginal zone (MZ) B cells, which have mixed attributes of naive and 
memory B cells135. Transitional B cells and MZ B cells respond to T cell- 
independent antigens139 and, together with mature naYve B cells, constitute the pre- 
immune/natural effector compartment.
1.5.2 B cell reconstitution following transplantation
Following BMT and HSCT, levels of circulating B cells are generally
undetectable within the first 2-3 months post-transplantation. Subsequently, B cells 
expand and circulating B cell counts transiently become supranormal by 1-2 years 
after grafting, finally stabilizing years after the transplantation procedure140-143. In 
most published reports, all circulating B lymphocytes are of donor origin after T cell- 
replete transplant with high intensity conditioning regimen; conversely, after T cell-
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depleted transplantation and after transplantation with low intensity or no 
conditioning regimen, a variable degree of incomplete chimerism of B cells is 
frequently established120,143. Generally, the rise is faster in young versus old 
individuals144, in autologous versus allogeneic marrow recipients and in patients 
who do not develop GVHD140,145. Indeed, GVHD and/or its treatment may hamper 
B-lymphopoiesis143,146,147. B cell recovery is also similar between myeloblative and 
non-myeloablative regimens, indicating no beneficial effects of reduced 
chemotherapy dose in this regard148.
Independently of the transplantation procedure, many studies reported that B 
cell development after transplantation recapitulates the normal ontogeny in terms of 
circulating cell types and numbers. Immunophenotypic analysis of B cell recovery 
in the early 1990’s reported the presence of undifferentiated B lymphocytes in the 
early phases post-transplant, as revealed by the expression of immature markers 
on the cell surface140,142. Post-transplant, donor B cells emerge initially with a naTve 
phenotype, lacking somatically mutated V(D)J genes149"151 and produce IgM and 
IgD rather than IgG or IgA140,152,153.
Memory B cells are scarce in the first 1-2 years post-transplant and develop 
up to 5 years later150,154. Consistent with this, it is reported that IgM levels recover 
first, within 2-6 months43,155, followed by IgG, which approaches normal levels 
between 3 and 18 months following transplantation, and IgA, the reconstitution of 
which may be delayed for up to 3 years43,155.
Ig levels are primarily of recipient origin early post-transplant, even in patients 
with complete chimerism of lymphocytes. This is because host plasma cells are 
relatively resistant to current preparative regimens and may persist for up to 2 
years after tranplant143,156,157 However, the delay in conversion to only donor-type 
antibodies is also a consequence of the compromised function of B cells due to the
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limited repertoire of T cells available to recognize and signal to their B cell 
counterparts37.
Memory B cells show skewing of Ig heavy chain complementary-determining 
region 3 (CDR3) loop patterns158,159 and a decreased rate of somatic hypermutation 
in mature B cells151. Thus, following transplantation, B cell immunity is impaired due 
to prolonged low levels of circulating B cell numbers, a relative deficit of mature B 
cells due to decreased isotype switching and a diminished ability to undergo 
somatic hypermutation.
The prolonged presence of immature and naYve B cells associated with the 
low frequency of fully functional memory B cells has been proposed to be, at least 
in part, responsible for the hyporesponsiveness of transplanted patients to 
vaccinations, even after normal B cell numbers have been achieved120,160*162.
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2 Aim of the study
HaploBMT combined with pt-Cy is changing the perspective of allogeneic 
transplantation because it allows the identification of suitable donors for patients 
who lack of HLA-matched donor. The infusion of unmanipulated BM, as it occurs in 
this protocol, would potentially allow the transfer of mature immune cells to the 
patient. Multiple subsets of T and B cells with different immune functions are 
infused with the BM, but it is unclear at present to what extent these cells can 
persist in the lymphopenic environment. Moreover, it remains to be determined 
whether pt-Cy spares non-alloreactive cells and thus favours immune reconstitution.
The main aim of this study is to evaluate the mechanisms that underlie 
reconstitution of the adaptive immune system following haploBMT combined with 
pt-Cy. Specifically, we used 18-color polychromatic flow cytometry and cell sorting, 
as well as molecular technologies (polyclonal and antigen-specific level,) to 
determine the persistence and expansion of T and B cells adoptively transferred 
with the graft.
We concentrated our efforts during the first few days/weeks post-BMT to 
investigate the mechanism of action of pt-Cy. Longitudinal analyses of blood 
samples were exploited to determine lymphocyte dynamics over time and to follow 
the maturation process of recovering lymphocyte populations.
In the case of T cells, we unconventionally exploited infection matched and 
mismatched donor/recipient pairs to investigate the contribution of cognate antigen 
to the persistence and expansion of transferred pathogen specific T cells.
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3 Methods
3.1 Experimental design
A total of 28 consecutive haploBMT patients were studied and none of them 
were excluded a priori from the analysis. All experiments display biological 
replicates from different patients or healthy donors that were randomly selected, 
unless specified (such as for the study of antigen-specific responses). The number 
of replicates used in experiments is indicated in the figure legends. PB specimens 
from patients were collected longitudinally, frozen then stored in liquid nitrogen and 
analyzed in batches by flow cytometry to minimize variability. Buffy coats from 
healthy donors were processed independently and used in control experiments.
3.2 Study subjects and transplantation procedures
Twenty-eight patients were treated in the Haematology and Bone Marrow 
Transplant Unit of Humanitas Cancer Center according to the haploBMT protocol 
established by Luznik et a/.3. Briefly, the conditioning regimen consisted of 14.5 
mg/kg Cy on day (d) -6 and d-5, 30 mg/m2 fludarabine from d-6 to d-2 and low-dose 
total body irradiation (200 CentiGray) on d-1. The GVHD prophylaxis consisted of 
50 mg/kg Cy administered on d3 and d4, tacrolimus (FK 506) and mycophenolate 
mofetil (MMF). FK (total dose 1 mg) was administered as a continuous infusion. 
MMF was administered orally at 15 mg/kg three times per day until d35 and then 
stopped. FK and MMF were started on d5. FK was tapered by d180. Granulocyte- 
colony stimulating factor (G-CSF) was started on d5 in all patients. HLA typing was 
performed on selected BM donors, who were considered haploidentical when at 
least one allele from the HLA-A, HLA-B, HLA-Cw, HLA-DRB1 and HLA-DQB1 loci 
matched the recipient. Additional details of the clinical protocol are available at
27
www.clinicaltrials.gov, protocol numbers NCT02049424 and NCT02049580. Patient 
characteristics are listed in Table 1. Patients and donors signed consent forms in 
accordance with the Declaration of Helsinki and with a related clinical and 
experimental protocol approved by the Institutional Review Board of Humanitas 
Research Hospital (Prot. Nr CE Humanitas 222/14).
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Table 1: Characteristics of the patients enrolled in the study. Abbreviations: HL,
Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; D/R, donor/recipient; CMV,
Cytomegalovirus; PR, partial remission; CR, complete remission; PD, progressive disease; SD, 
stable disease; RAA, Relapse after autologous; TAA, Tandem autologous-allogeneic; HR, High- 
risk; Ref, Refractory; RAallo, relapse after allogeneic transplantation; NA, not applicable; AS, 
developed after sampling was stopped; ECP, Extracorporeal photochemotherapy; NA, not 
applicable; Gl, Gastrointestinal; EBV, Epstein-Barr virus; JC, John Cunningham polyomavirus; 
S. Epidermidis, Staphylococcus Epidermidis; BK, BK polyomavirus; ESBL E. Coli, Extended- 
spectrum beta-lactamase-producing Escherichia Coli; S. aureus, Staphilococcus aureus; E. 
faecalis, Enterococcus faecalis; A. Fumigatus, Aspergillus Fumigatus; HHV6, Human Herpes 
Virus 6; C. Difficile, Clostridium Difficile; RSV, Respiratory Syncytial Virus S. Maltophilia, 
Stenotrophomonas Maltophilia; HSV, Herpes Simplex Virus; P. aeruginosa, Pseudomonas 
aeruginosa. Notes: *: the patient stopped coming to the clinic.
3.3 Sample collection
Peripheral blood (20 to 100 mL) and BM (5 mL) specimens were obtained 
from the Haematology and Bone Marrow Transplant Unit of Humanitas Cancer 
Center. PB was drawn in heparinized tubes from donors and recipients before 
transplantation and from recipients every week until d98, then every month until 
one year after transplantation (Figure 2). BM was also collected during the 
aspiration procedure. Buffy coats of healthy donors were obtained from S. Gerardo 
Hospital (Milan, Italy) under Institutional Review Board exemption. PBMCs and BM 
cells were obtained by Ficoll-Paque Premium (GE Healthcare) density gradient 
centrifugation and frozen in liquid nitrogen according to standard procedures163.
Doints D -6 0 3 1 2 3 4 5 6 7 8 9  10 11 121314 4 5 6 7 8 9  10 12. > // .............. — — .................................... — — y / -
N° of patients 
T cell
analysis 9 13 11 13 13 1613 13 13 7 9 8 10 4 4 5 8 5 5 6 7 2 5 5 2 4
B cell
analysislO 9 4 2 7 7 7 5 5 6 7 5 4 4 5 3 3 6 4  4
Figure 2: Schematic representation of the transplantation procedure. The number of 
patients phenotyped at each time point to analyze T and B cell subsets is indicated at the 
bottom row.
BMT CyCy
Time Weeks Months
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3.4 Polychromatic flow cytometry, phenotyping and 
cell sorting
For analysis of the T cell compartment, the following anti-human monoclonal 
antibodies (mAbs) were used: CD3 (clone SP-34.2 and OKT3), CD4 (SK3 and 
OKT4), CD8 (RPA-T8), CD45RA (HI100), CD45RO (UCHL1), CCR7 (150503), 
CD27 (0323 and 1A4CD27), CD95 (DX2), CD31 (WM59), Ki-67 (B56), CD57 
(HNK-1), HLA-DR (G46-6), IL-2 (MQ1-17H12), IFN y (B27), TNF (Mab11), CD127 
(A019D5), CD25 (M-A251), HLA-A2 (BB7.2), HLA-B7 (BB7.1, from Millipore) and 
CD14 (M5E2). For analysis of the B cell compartment, the following anti-human 
mAbs were used: CD19 (HIB19), CD20 (2H7), CD10 (HI10a), CD38 (HIT2), CD21 
(B-ly4), IgM (G20-127) IgD (Polyclonal and IA6-2), IgG (G18-145), CD5 (UCHT2), 
CD27 (1A4LDG), CD14 (TuK4) Life Technologies, CD3 (OKT3), CD8 (RPA-T8), 
CD4 (M-T477), Ki-67 (B56), HLA A2 (BB7.2).
Fluorochrome-conjugated mAbs were purchased from BD Biosciences, 
Biolegend, BD Horizon, BD Pharmingen, Dako and Life Technologies, or 
conjugated in the laboratory of Dr. Mario Roederer from purified unlabeled mAbs 
(BD Biosciences). In-house conjugation was performed according to the protocols 
reported at http://www.drmr.com/abcon.
All antibodies were titrated on human PBMCs and used at the concentration 
giving the highest signal-to-noise ratio over background, as described164. Co- 
staining with multiple reagents at the same time validated the specificity of the 
staining. Anti-HLA class I antibodies were tested on individuals with or without 
expression of the relevant HLA molecule, as determined by HLA typing.
Frozen cells were thawed in RPMI1640 supplemented with 10% fetal calf 
serum, 1% penicillin-streptomycin and 1% L-glutamine (all from Life Technologies) 
containing 50 U/mL Benzonase nuclease (EMD Biochemicals) and stained.
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In all experiments, cells were stained for 15 min at room temperature (RT) 
with a live/dead fixable dead cell stain kit (Life Technologies) to eliminate dead 
cells, which may influence the analysis. After that, cells were stained with for 20 
min at RT with a combination of mAbs specific for surface proteins, as described 
previously72. Chemokine receptor expression was revealed by incubating cells at 
37°C for 20 min with the relevant mAb. The Cytofix/Cytoperm kit (BD Biosciences) 
was used according to the manufacturer's protocol to detect intracellular Ki-67 
expression .
T cell subsets were defined as follows, unless indicated otherwise: recent 
thymic emigrant T ( T rTE) CD4+ cells, CD45RO“CCR7+CD27+CD45RA+CD95" 
CD31+; T n CD4+ cells, CD45RO“CCR7+CD27+CD45RA+CD95"CD3r (for CD8+ T 
cells, TNwere defined as CD45RO"CCR7+CD27+CD45RA+CD95", irrespective of 
CD31 expression); T s c m , CD45RO”CCR7+CD27+CD45RA+CD95+; T cm, 
CD45RO+CCR7+; Ttm, CD45RO+CCR7"CD27+; Tem, CD45RO+CCRrCD2r; and, 
T t e , CD45RO~CCR7“. Figure 3 displays the gating strategy used for analyzing T 
cell subsets.
B cells were defined as follows: transitional B cells, CD38bnghtCD10+ cells; 
mature B cells, CD38d,mCD10". In the mature B cell compartment, naTve B cells 
were defined as lgM+ or lgD+, and memory B cells were defined as IgMlgD” and 
include IgG* and lgG~ cells. In the transitional compartment, the following subsets 
were also defined: T1 (CD5+CD21”), T2 (CD5+CD21+), T3 (CD5”CD21+) and CD5" 
CD21" cells, here named TO. Figure 4 displays the gating strategy used for B cell 
subsets analysis.
To minimize technical variability, samples from the same patient were 
analyzed in batches. Samples were acquired on a LSRII or Fortessa flow cytometer 
(BD Biosciences), equipped for the detection of 20 parameters. A FACS Aria II cell
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sorter (BD Biosciences) was used to separate cell subpopulations. Absolute counts 
of T and B cell subsets were obtained by calculating the percentage of live CD3+ 
and CD20+ cells respectively, within the lymphocyte gate. Absolute lymphocyte 
numbers per pL of PB were obtained from the Flow Cytometry Core Facility of the 
Haematology and Bone Marrow Transplant Unit at the Humanitas Cancer Center.
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Figure 3: Gating strategy used to identify T cells at different stages of maturation by 
polychromatic flow cytometry. CD4+ and CD8+ T cells are identified by gating on CD3+,
CD 14" and Aqua Live/Dead" cells. Gating on CD4+ T cells, T Te are identified as CD45RCT 
CCR7~; T cm are CD45RO+CCR7+; effector-like cells are CD45RO+CCR7_ and further 
distinguished on the basis of CD27 expression as Ttm (CD27+) and TEM (CD27- ); T Scm are 
CD45RO"CCR7+CD27+CD45RA+CD95+; Trte are CD45RO"CCR7+CD27+CD45RA+CD95" 
CD31+; T n are CD45RO"CCR7+CD27+CD45RA+CD95'CD31“ . For CD8+ T cells, TN were 
defined as CD45RO“CCR7+CD27+CD45RA+CD95_, irrespective of CD31 expression. A similar 
gating strategy was used for CD8+ T cells.
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Figure 4: Gating strategy used to identify B cells at different stages of maturation 
by polychromatic flow cytometry. B cells are identified by gating on CD20+CD3XD14~Aqua 
Live/Dead" cells. Gating on CD10+CD38+ B cells, transitional B cells are identified. In this 
compartment, T1 (CD5+CD21“ ), T2 (CD5+CD21+), CD5XD21* and CD5XD21-  cells, named
TO, are distinguished. Mature B cells are identified as CD38 CD10~. Gating on mature B cells, 
naive B cells are defined as lgM+ and/or lgD+, whereas memory B cells are defined as lgM~lgD~ 
and include lgG+ and IgG" cells.
3.5 Analysis of donor chimerism
DNA was obtained from sorted live CD3+CD56XD20XD14~ T cells and 
sorted live CD3XD56XD14XD19* B cells from PB using a Qiamp Blood Mini Kit 
(Qiagen) according to the manufacturer’s instructions. T cells and B cells were 
sorted from three patients at the following time points post-haploBMT: d63, d91 and 
d126. DNA quantification was performed using a photometer (BioPhotometer, 
Eppendorf). Sixteen polymorphic short tandem repeat markers were amplified 
using a multiplex PCR fluorescent approach (AmpFISTR Identifier Plus, Applied 
Biosystems) on an ABI 9700 thermal cycler (Applied Biosystems). The reaction 
mixture was set up using 25 ng DNA to evaluate at least 3,000 cells as described 
previously166. At least five of these informative loci were amplified using a 
singleplex Quantitative Fluorescent PCR approach. Primer sequences were
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obtained from the UniSTS database (www.ncbi.nlm.nih.gov). PCR products were 
run on a Capillary Electrophoresis System (ABI 310, Applied Biosystems) and 
analyzed using GENESCAN 3.1.2 software. Single PCR products were visualized 
in electropherograms as peaks variable in length and color. Residual mixed 
chimerism was calculated on the basis of the relative length of donor and recipient 
alleles as described previously166.
3.6 T cell stimulations and treatments
PBMCs or sorted T cell subsets were seeded at a final density of 0.25x106 
cells/mL unless indicated. Cell proliferation was determined by the analysis of 5- 
(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFSE; Life Technologies) 
dilution. Cells were stained at 37°C for 7 min at a final concentration of 5 mM, 
washed extensively in complete medium and subsequently stimulated with 1 or 50 
ng/mL rhlL-15 (Peprotech) for 8-10 days. Patients’ PBMCs at different times post- 
haploBMT (n=5; d41, d53, d56, d57 and d65) were used to generate Figure 12B.
To induce effector cytokine production, PBMCs were cultured in 96-well 
plates (final volume: 200 nL) and stimulated with phorbol 12-myristate 13-acetate 
(PMA; 10 ng/mL) and ionomycin (500 ng/mL, both from Sigma Aldrich) for 4 hr in 
the presence of GolgiPlug (BD Biosciences) according to the manufacturer’s 
instructions. To detect antigen-specific T cells by intracellular cytokine staining, 
PBMCs were stimulated for 16 hrs with a CMV peptide pool spanning the entire 
region of the pp65 protein (15mer peptides overlapping by 11 residues; JPT 
Technologies; final concentration 1 mg/mL/peptide) or with VAXIGRIP® seasonal 
influenza vaccine (Sanofi; obtained from the local pharmacy; used at 1:40 vol/vol). 
Intracellular cytokine production was revealed as described previously165.
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In mixed lymphocyte reaction (MLR) cultures, highly-purified Tn and memory 
T cell subsets were cultured at a ratio of 1:1 with autologous APCs (auto-APCs) or 
MHC-mismatched APCs (allo-APCs) for the times indicated in the text. APCs were 
sorted from PBMCs as CD3"CD56" mononuclear cells. To block APC:T cell 
interactions, anti-MHC class I and class II blocking antibodies were used (clones 
G46-2.6 and Tu39, respectively; both used at 10 mg/mL). Non-alloreactive T cells 
were identified by either gating on CFSEh,gh cells or on cells negative for both CD25 
and CD69 activation markers.
3.7 Enumeration of antigen-specific T cells by MHC 
class I tetramers
The following recombinant pMHCI tetramers, produced as described 
previously167, were used: HLA-A*0201 presenting CMV pp65495_503 NLVPMVATV 
(NV9), HLA-A*0201 presenting influenza matrix proteinss^ GILGFVFTL (GL9), 
HLA-A*0201 presenting melanoma antigen recognized by T cells 1 (MART-1 )26-35 
ELAGIGILTV, HLA-A*0201 presenting Wilms’ Tumor 1 (WT1 )37-45 VLDFAPPGA, 
HLA-A*0201 presenting WT1i26-i34 RMFPNAPYL, HLA-A*0201 presenting WT1235- 
243CMTWNQMNL, HLA-A*0301 presenting influenza nucleoprotein265-273 
ILRGSVAHK (IK9) and HLA-A*B07 presenting CMV pp654i7-426 TPRVTGGGAM 
(TM10). The human CD1d tetramer loaded with the a-galactosylceramide analog 
PBS57 was provided by the NIH Tetramer Core Facility. Tetramers were 
conjugated with streptavidin-BV421 (Biolegend), PE (Sigma) and APC (Life 
Technologies). Tetramer staining was conducted at 37°C for 15 min. To detect 
WT1+ cells, tetramers recognizing 3 different WT1 epitopes were combined in the 
same channel. Given the large number of cells needed for the quantification of 
WT1+ T cells, PBMCs from blood bank donors instead of marrow donors were used.
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CD8+ T cells were enriched by negative magnetic sorting (Stem Cell Technologies) 
from 10-30x106 PBMCs prior to staining. Between 0.3 and 3x106 total CD8+ T cells 
were acquired. For MART-1 and WT1, the percent threshold of positivity (0.003926 
and 0.003705, respectively) was calculated by analyzing the 75th percentile of 
distributions resulting from the percentage of tetramer-binding cells in the CD4+ T 
cell compartment. Only one representative threshold is depicted in Figure 16D for 
simplicity.
3.8 Clonotypic analysis of antigen-specific CD4+ and 
CD8+ T cells
Preliminary peptide mapping experiments were conducted to identify donor 
and recipient CMV-specific CD4+ and CD8+ T cells responding to the same pool of 
12 overlapping peptides spanning the CMV pp65 protein, as described168. Aqua” 
CD14“CD3+CD4/CD8+ T cells producing IFNy or TNF in the memory pool were 
subsequently sorted into 1.5 mL microfuge tubes (Sarstedt) containing 200 uL of 
PBS. A median of 3901 (range: 712-30,030) specific cells were sorted per sample 
from up to 80x106 PBMCs. Clonotypic composition was determined in collaboration 
with Professor David Price using a DNA-based multiplex PCR for TCRB gene 
rearrangements as described previously169.
3.9 Statistical analysis
Analysis was performed using GraphPad PRISM (6.0b) and SPICE 5.22 
software170. The non-parametric paired Wilcoxon rank test and the unpaired Mann- 
Whitney test were used to compare two groups. Differences in the pie chart
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distributions were calculated with SPICE software using a permutation test. P 
values are two-sided and were considered significant when £ 0.05.
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4 Results
4.1 Immune reconstitution is donor-dependent
In Luznik’s protocol, a non-myeloablative conditioning regimen is used as 
chemotherapeutic treatment before transplantation. So, after BMT, donor immune 
cells infused with the transplant, as well as chemotherapy-resistant recipient 
immune cells, may coexist in the recipient. We sought to determine whether the 
reconstituting PB B cells in the transplanted patients derived from the donor or the 
recipient.
In collaboration with Dr. B. Cassani and Dr. G. Bulfamante (Unit of Pathology 
of San Paolo Hospital, Milan, Italy), we performed donor-recipient chimerism 
analysis of PB leukocytes of all patients who had received haploBMT, within 120 
days post-transplantation. This analysis revealed that more than 98% of the 
circulating leukocytes in the recipient carried donor alleles, as also reported by our 
clinical team26.
However, to exclude a bias due to the presence of high proportions of non-T 
cells and non-B cells that could misread the actual T and B cell chimerism, we 
sorted live CD3+CD56_CD20~CD14~, either expressing CD4 and CD8, and live 
CD3"CD56"CD14~CD19+ circulating B lymphocytes to high purity from 3 patients 
during immune cell reconstitution (d63, d91 and d126) and performed chimerism 
analysis on the sorted cells (Figure 5). The data obtained were very similar to those 
obtained with total PBMCs and confirmed that more than 99% of the circulating T 
and B cells detected in the recipients derived from the marrow donors (Figure 5). 
Finally, we also measured the donor chimerism at the single cell-level by the flow 
cytometry using antibodies specific for the mismatched HLA (e.g. HLA-A*02, HLA- 
B*07) combined with antibodies to identify T cells and B cells, thus validating the
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donor origin of the reconstituting PB T and B cells following haploBMT. These data 
are reported in the following sections (Figure 6B, Figure 17B). Overall the results 
indicate that only donor T and B immune cells play a role in the peripheral immune 
recovery.
Host
Donor
0.5 0.3
CD4+ cells CD8+ cells CD19+ cells
Figure 5: Proportions of donor-recipient T and B cells 2 months after transplant.
Proportions of donor-derived (gray) and residual host (black) cells in FACS-sorted CD4+ and 
CD8+ T cells and in FACS-sorted CD19+ B lymphocytes. The reported data are the median of 3 
BM recipients. Cells were sorted from the 3 patients at d62, 91 and 126 after BMT, respectively. 
Numbers indicate the proportion of residual recipient cells.
4.2 T cell reconstitution after transplantation
4.2.1 High frequency of T Scm in the PB before reconstitution
It is well known that in response to antigen or lymphopenia, T cells undergo
activation and rapidly start to proliferate and acquire an effector phenotype, 
represented by the lack of CD45RA and CCR7 and by the expression of 
CD45R075,114,121,171. At d3 following BM infusion, the vast majority of circulating T 
cells expresses markers of proliferation (Ki-67) and activation (HLA-DR+; Figure 
6A). These cells acquire the CD45RO+CD45RA“CCR7_ effector phenotype 
irrespective of their original differentiation status, thus determining the higher 
frequency of CCR7~CD45RO+ T cells observed in Figure 6A at d3.
It is also known that Cy preferentially depletes proliferating cells. As 
expected35, in vivo treatment with high dose of Cy, given at d3 and d4 after 
transplantation, depleted activated and proliferating cells almost completely at d7
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post-haploBMT, leaving a population of relatively quiescent T cells (Figure 6A) and 
allowing the identification of immune T cell phenotypes preceding the initiation of 
reconstitution without bias. Given that only donor T cells are responsible for 
peripheral T cell reconstitution, as shown in Figure 5 and also assessed by the 
analysis of donor HLA type at the single cell-level (Figure 6B), we extensively 
analyzed the phenotype and maturation status of recipient and donor T cells by 18- 
color flow cytometry to identify correlates of persistence in vivo. Based on previous 
data72,83, multiple markers were used simultaneously to accurately identify T cell 
phenotypes, as indicated in Methods (Chapter 3.4, Figure 3). While recipient cells 
preferentially expressed a memory phenotype (with some differences between the 
CD4+ and CD8+ T cell compartments in terms of T c m , T Em and T i e  cell distribution; 
Figure 6C, D), including activated (HLA-DR+) and senescent (CD57+) cells80 (Figure 
6C), donor cells predominantly displayed a T Scm  phenotype, characterized by the 
co-expression of multiple naYve-associated antigens as well as by the T scm  core 
phenotypic marker CD9571,75 (Figure 6C,D). The frequencies of T scm  among the 
donor populations largely exceeded those observed in the corresponding grafts, 
both for CD4+ and CD8+ T cells (Figure 6D), and in the PB of healthy donors 
(typically 2-3% of total T cells)71. In the following weeks, T scm  were replaced by 
more differentiated T Cm and T Em cells (Figure 6E). Subsequently, a longitudinal 
analysis of the absolute counts of CD3\ CD4+ and CD8+ T cells (Figure 6F), and 
also CD4+ and CD8+ T cell subsets (
Figure 7), was performed. Rapid increases were observed from week 6 post- 
haploBMT, when the immunosoppressive drug MMF was discontinued, that were 
followed by equally rapid declines at week 9. These were possibly caused by the 
apoptotic loss of highly-activated effector cells, as proposed previously123.
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Subsequently, T cells progressively recovered over time (Figure 6F). These 
dynamics paralleled the rate of proliferation of multiple T cell subsets (Figure 8). 
During recovery, T cells displayed a predominant TTm, TEm or Tie cell phenotype 
and tended to normalize only at 1 year post-haploBMT, when CD4+ T rte  and CD8+ 
Tn appeared (Figure 6G;
Figure 7). Tscrrphenotype cells are thus highly enriched early after 
transplantation and might contribute to subsequent T cell recovery.
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Figure 6: TScm dominate the T cell compartment before reconstitution. (A)
Representative (out of 10) CD45RO/CCR7 (top) and Ki-67/HLA-DR (bottom) expression on PB 
CD3+ T cells in the donor (D) and in recipient (R) at d3 and d7 post-haploBMT. (B) Longitudinal 
identification of donor (D) and recipient (R) CD3+ T cells by analysis of the mismatched HLA (in 
this case HLA-A*02) via flow cytometry. (C) Simultaneous analysis of differentiation and
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activation markers on PB T cells at d7 post-haploBMT. Donor (D; red) and recipient (R; dark 
grey) cells are identified by antibody recognizing the mismatched HLA-A*02 (expressed by 
recipient T cells). Light grey cells in the background are T cells from the PB of a healthy donor. 
(D) Median±Standard error of the mean (SEM) frequency of D and R T cells (identified as in C) 
with a given differentiation phenotype in patients at d7 post-haploBMT (n=4). Only donor- 
recipient pairs whose mismatched HLA could be investigated by flow cytometry are included. 
*=P<0.05 vs. d7 D cells; Mann-Whitney test. (E) CD45RO/CCR7 expression on T cells at 
different times post-haploBMT. Numbers in the flow cytometry plots indicate the percentage of 
cells identified by the gates. (F) MeantSEM absolute counts of CD3+, CD4+ and CD8+ T cells. 
(G) Relative median proportion of T cell subsets post-haploBMT. *=P<0.05; permutation test. 
Details on the number of patients at each time point displayed in F-G are indicated in Figure 2. 
RIC: reduced intensity conditioning regimen; MMF: mycophenolate mofetil; mo: months; d: day; 
N/A: Not applicable.
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Figure 7: T cell subsets dynamics following haploBMT. Mean±SEM absolute counts 
(cells/pL) of T cell subsets from patients following BMT and related donors. The number of 
patients at each time point is indicated in Figure 2. # = P<0.05 vs. Donor; Mann-Whitney test.
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Figure 8: Proliferation of multiple memory T cell subsets during reconstitution.
MeaniSEM expression of Ki-67 by memory T cell subsets during T cell recovery. TRTe and TN 
cells were omitted as no relevant expression of Ki-67 could be detected. Week 5 post- 
haploBMT corresponds to MMF discontinuation and week 6 to peak T cell proliferation in the 
majority of the subsets. Details on the number of patients at each time point are indicated in 
Figure 2. # = P<0.05 vs. Donor; Mann-Whitney test.
4.2.2 Non-alloreactive TN survival in response to pt-Cy
Given the preferential sensitivity of proliferating cells to Cy, we investigated
whether different subsets of T cells have a specific in vivo expression of the 
proliferation marker Ki-67 before Cy treatment (i.e., d3 post-haploBMT). We found 
that CD4+ Trie and both CD4+ and CD8+ TN were almost exclusively Ki-67- at this 
time point, while memory T cells tended to express larger amounts of Ki-67 with 
progressive differentiation (Figure 9A). This was more evident for CD4+ than for 
CD8+ T cells. The former also proliferated less compared to CD8+ T cells (Figure 
9A). Similar trends were confirmed by gating on donor-derived T cell subsets 
(Figure 9B). Similar to conventional CD4+ T cells, CD4+CD25++CD127- T regulatory
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cells ( T r e g ) (Figure 9C) with a naive phenotype (i.e., CD45RO"CCR7+CD45RA+) 
(Figure 9D,E) preferentially survived Cy treatment (Figure 9D), as recently 
reported172, due to their lower proliferation rate compared to memory cells at d3 
post-haploBMT (Figure 9F). As a result of increased Ki-67 expression by CD8+ T 
cell subsets at d3 and the sensitivity of proliferating cells to Cy, the depletion of 
CD8+ T cells and the increased frequency of CD4+ T cells was observed following 
Cy treatment in vivo (Figure 9G).
It has been proposed that memory T cells are relatively resistant to Cy 
treatment compared to T n25. This is based on mouse studies where allogeneic 
effector cells were transferred from donor mice following immunization with host 
cells for 7 days32 or on human studies where unfractioned CD4+ T cells were 
treated with Cy in vitro'12. To better clarify the cellular mechanisms of Cy-mediated 
depletion of T cells, we set up MLR cultures by using highly-purifed naYve or 
memory T cell subsets and allo-APCs. Auto-APCs were used as a control. T cell 
activation induces rapid changes in surface phenotypes, including the loss of 
CD45RA and the up-regulation of CD45RO expression, thereby leading to the 
hypothesis that the Ki-67+ memory fraction observed at d3 (Figure 9A) also 
contains allogeneic T cells derived from the Tn pool. Incubation of CD4+ Tn or 
CD45RO+ T mem  with allo-APCs but not auto-APCs for 3 days led to the proliferation 
(CFSE dilution) and up-regulation of the activation marker CD25 in a fraction of T 
cells (Figure 10A), indicating that alloreactivity resides in both subsets. CFSE|0W 
cells from the Tn pool, originally FACS-sorted as CD45RO", uniformly up-regulated 
CD45RO compared to CFSEh,gh cells (Figure 10B). This was even more evident at 
d5 of culture (Figure 10C,D). Collectively, these results indicate that the Cy- 
sensitive Ki-67+ fraction observed at d3, exclusively identified by memory
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phenotypes, contains proliferating cells originating from both the TN and the 
memory T cell compartments.
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Figure 9: Non-alloreactive TN preferentially survive pt-Cy. (A) Mean±SEM frequency 
(n=10; each dot represents a patient) of Ki-67+ T cells with a given differentiation phenotype at 
d3 post-haploBMT. +, *: P<0.05 vs. T RTe and TN) respectively; Wilcoxon test. (B) Donor and 
recipient T cell subsets at d3 post-haploBMT identified as in Figure 2 were analyzed for the
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expression of Ki-67. Tmem: CD45RO+ T cells. Similar data were obtained from two more 
patients. (C) Identification of CD4+ T REg as CD25++CD127~ in the marrow donor and in the 
related recipient at d3 post-haploBMT. (D) CD45RO and CCR7 expression by T REg identified in 
C before (d3) and after (d7) in vivo Cy. Note the increase in the proportion of CD45RO“CCR7+ 
naive-like cells. (E) Representative CD45RA expression by TN (CD45ROXCR7+), T Cm 
(CD45RO+CCR7+) and TEM (CD45RO+CCR7~) TREG cells from a healthy donor. (F) Summary of 
Ki-67 expression in TREG subsets from patients (n=6) at d3 post-haploBMT. *, P<0.05 vs. TN; 
Wilcoxon test. (G) Mean±SEM frequency (n=13) of CD4+ and CD8+ T cells at d3 and d7 post- 
haploBMT. P<0.05 vs. d3; Wilcoxon test.(B-D) Numbers indicate the percentage of cells 
identified by the gates. D: donor; R: recipient.
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Figure 10: Alloreactive TN acquire memory phenotypes. (A) CFSE dilution and CD25 
expression by T n  and Tmem following incubation with auto-APCs or allo-APCs for 3 days. The 
gate in black identifies CFSE|0W proliferating cells while that in grey CFSEhigh non-proliferating 
cells. (B) CD45RO expression by CFSE|0W and CFSEhigh TN (top) and Tmem (bottom) cells 
identified as in A. (C) CFSE dilution and CD25 expression following 5 days of incubation with 
auto-APCs or allo-APCs. (D) CD45RO expression by CFSEl0W and CFSEhigh TN (top) and T MEm 
(bottom) cells identified as in C.
4.2.3 TN-origin of post-transplant T Scm
Given the preferential depletion of Ki-67+ T cells by Cy treatment, it seemed 
unlikely that the high frequency of TScM-phenotype cells observed at d7 originated
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from the proliferation of a pre-existing T scm  population. Moreover, T cells were still 
Ki-67~ at d7 (Figure 6C), indicating that proliferation did not commence after pt-Cy, 
at least in the blood. We thus reasoned that T scm  derived from the differentiation of 
adoptively-transferred TN. To validate this concept, we followed the expression of 
CD31, a marker preferentially expressed by early-differentiated CD4+ T RTe 173 and 
down-regulated in CD4+ T scm  and T m em 71- CD8+ T cells were not studied in this 
regard, as CD31 has no value in the identification of CD8+ T r ie -
Before transplantation (dO), very few recipient cells could be observed in the 
CD45RO“CCR7+ naive-like gate (NL; i.e. comprising both T n and T s c m ), thus 
obviating the need to differentiate between donor and recipient cells to follow this 
population of cells (Figure 11 A). These NL cells also expressed additional naYve 
markers, i.e., CD45RA and CD27 (not shown). NL-CD4+ T cells infused with the 
BM were mostly CD95~ but progressively acquired CD95 expression within both the 
CD31+ and the CD31“fractions (Figure 11B). This phenotypic shift was 
independent of pt-Cy, as in vitro mafosfamide treatment did not induce CD95 in 
FACS-sorted Tn (data not shown).
At d7 post-haploBMT, T Scm  expressed CD31 at frequencies similar to those of 
T n and higher than those of T scm  from the blood of the related donors (Figure 11C), 
further corroborating the idea that they derived from differentiation of transferred TN. 
To exclude the possibility that CD95 up-regulation occurred non-specifically on all T 
cells, we calculated the fold change in CD95 expression in different CD4+ and 
CD8+ T cell subsets between d3 and d7, and found that it increased only in NL T 
cells (Figure 11D). Moreover, in vitro incubation of Tn with allo-APCs led to CD95 
up-regulation in the non-alloreactive fraction compared to incubation with auto- 
APCs (Figure 11E,F), thereby indicating that acquisition of the TscM-phenotype may 
occur in the allogeneic environment. Such an increase could be prevented by the
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addition of anti-MHC class II (for CD4+) and class I (for CD8+) blocking antibodies 
(Figure 11E,F).
Alternatively, to test whether d7 TscM-phenotype cells derived from the 
proliferation of pre-existing donor T scm  (either CD31+ or CD31"), we FACS-sorted 
CD31+ T r ie  as well as CD31" TN, T Scm  and T mem  (Figure 11G) and incubated them 
with allo-APCs to monitor CD31 expression in the proliferating (CFSE10) population. 
CD31+ T scm  could not be tested due to low recovery after FACS-sort. T r ie  lost 
CD31 expression upon CFSE dilution and memory differentiation (Figure 11H). 
Accordingly, CD31" subsets failed to reacquire CD31 (Figure 11H). Collectively, our 
results exclude the possibility that d7 T scm  originated from pre-existing T scm  and 
substantiate their differentiation from adoptively-transferred Tn.
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Figure 11: Post-transplant TScm differentiate from TN. (A) Representative frequency 
(out of 12) of CD45RO~CCR7+ T cells in a patient a dO and d3 post-haploBMT. (B) 
Representative (out of 12) CD31 and CD95 expression on nai've-like (NL) CD4+ T cells from the 
BM of a donor and from the PB of the related recipient at different times post-haploBMT. NL: 
CD45RO~CCR7+CD45RA+CD27+. Numbers in the flow cytometry plots indicate the percentage 
of cells identified by the gates. (C) Mean±SEM CD31 expression on PB CD4+ TN and T Sc m  from 
marrow donors (D) and CD4+ T Sc m  from the related recipients (R; n=12) at d7 post-haploBMT. *: 
P<0.05 vs. D T s c m ! Wilcoxon test. (D) Fold change in CD95 median fluorescence intensity (MFI) 
in different T cell subsets between d3 and d7. *: PO .05 vs. NL; Wilcoxon test. (E) 
Representative analysis of CD95 expression by TN following incubation with different stimuli. (F) 
Summary of the data obtained as in E (n=8, analyzed in 4 independent experiments: *: P<0.05
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vs. allo-APCs, Wilcoxon test). (G) CD45RO and CD31 expression by FACS-sorted Trte, CD31" 
Tn and CD31~Tmem- Around 2,000 sorted cells are shown. Numbers indicate the final purity of 
the sorted population. (H) CFSE dilution and CD31 expression by FACS-sorted T cell subsets 
following incubation with allo-APCs for 5 days.
4.2.4 Memory attributes of post-transplant TScm
The acquisition of the TScM-phenotype following pt-Cy may have occurred
spuriously in Tn. To assess whether T scm  differentiation occurred also at the 
functional level, we tested the ability of TscM-phenotype cells from patients to 
respond to IL-15 (for CD8+) and produce effector cytokines following 
pharmacological stimulation with PMA/ionomycin (for both CD4+ and CD8+). We 
first attempted to do this in T cells isolated at d7 or during the early weeks after 
haploBMT. However, the cells failed to survive in vitro following IL-15 stimulation or 
were unresponsive to PMA/ionomycin treatment (not shown), presumably due to 
the exposure to immunosuppressive drugs in vivo.
To overcome this, we repeated the experiment in samples from later time 
points, i.e. d41 and d65 after haploBMT. As CD8+ T Scm  could not be purified by 
FACS due to their paucity, we analyzed the proliferative potential of different T cell 
subsets after in vitro culture of the whole PBMCs population. In previous 
experiments, purified T scm  and memory T cells were shown to change phenotype 
only slightly following IL-15 stimulation71. T scm  from patients between d41 and d65 
post-haploBMT diluted CFSE similarly to CD45RO+ T m em  (Figure 12A,B). 
Conversely, in line with previous experiments, TN from healthy donors did not dilute 
CFSE in response to IL-15 (Figure 12A,B).
To further prove that cells with a T Scm  phenotype possess memory attributes, 
PBMCs from haploBMT patients were stimulated with PMA/ionomycin and their 
effector cytokine production profile was determined. In vitro treatment with these 
agents did not change the relative proportion of T cell subsets among CD4+ and
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CD8+ T cells (Figure 1 2 C ) .  Tscm displayed a combination of IFN y, IL-2 and TNF 
expression similar to that of naturally occurring Tscm, but distinct from the functional 
profiles of TN and T Mem from healthy donors (Figure 1 2 D ) .  This combination is 
reminiscent of the functionality of Tscm in nonhuman primates73. Collectively, these 
data show that TN-derived T Scm acquire T Scm memory properties after BMT in vivo.
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Figure 12: Post-transplant Tscm  possess attributes of naturally occurring Tscm - (A)
Percent CFSE|0W CD8+ T cell subsets from a healthy donor (HD) and a recipient (R) at d41 post- 
haploBMT after PBMCs culture with 1 ng/mL (grey histogram, serving as a non-proliferating 
control) or 50 ng/mL (black histogram) IL-15 for 8 days. CD95~ Tn were not detected (N/D) in 
CD8+ T cells from Rs ex vivo (not shown) or after stimulation with IL-15. (B) Mean±SEM 
CFSEl0W CD8+ T cell subsets (calculated as in A) from HD (n=6) and haploBMT patients. TMem^ 
CD45RO+ memory T cells. *= P<0.05; Mann-Whitney test. (C) Frequency (median±SEM) of TN, 
Tmem (CD45RO+) and T Scm in unstimulated PBMCs from healthy donors (n=4) or after 
stimulation with PMA/ionomycin for 4 hr. (D) Combinations of intracellular IFN y. IL-2 and TNF 
production following PMA/ionomycin stimulation for 4 hr in gated T Scm from patients (n=3; at 
d35, d42 and d49 post-haploBMT) and in T cell subsets from healthy donors (HD; n=4). 
*=P<0.05; permutation test.
4.2.5 Poor expansion of adoptively-transferred memory T cells 
post-transplant
Next, we addressed whether antigen-specific memory T cells may survive pt-
Cy and expand in the host, either in the presence or in the absence of the cognate 
antigen. For this purpose, we analyzed the dynamics of multiple antigen-specific T 
cell populations transferred with the graft. We confined our analysis to -90 days 
post-haploBMT to exclude the generation of new TN by resumed thymic output123. 
The virtual absence of CD4+ Trie at this time point (
Figure 7) further supports this observation.
We used polychromatic flow cytometry combined with fluorescently-labeled 
MHC class I tetramers and in vitro antigen stimulation followed by intracellular 
cytokine staining to determine the frequency and phenotype of T cells specific for 
exogenous antigens. Antigen-specific CD8+ T cells, predominantly exhibiting a 
memory phenotype (Figure 13A,B), were present at similar frequencies in the BM 
and PB of marrow donors, as demonstrated for Flu and CMV-specific memory 
CD8+ (Figure 13C), thus justifying the use of PB cells when patient BM was 
unavailable. CD8+ T cells specific for Flu epitopes restricted by HLA-A*02 or HLA- 
A*03 were detectable in the PB of marrow donors but undetectable in the recipients 
up to 90 days after haploBMT (Figure 14A,C).
54
Interestingly, CD3+ natural killer T (NKT) cells recognizing the a- 
galactosylceramide analog PBS57 declined as well (Figure 14C). These specific 
cells, as well CMV-specific T cells, were also quiescent (Ki-67"), i.e., not 
preferentially susceptible to pt-Cy at the time of transfer (Figure 13A,B). Similarly, 
adoptively transferred CMV-specific CD4+ and CD8+ T cells from a CMV+ donor 
could not be detected in a CMV~ recipient (Figure 14B,C), as previously reported174. 
Flu-specific CD4+ T cells responding in vitro to the seasonal influenza vaccine 
(FluVAX) behaved in the same way (Figure 14C). It has been demonstrated that 
early differentiated memory T cells better persist and expand in vivo following 
adoptive transfer175,176. In our setting, the relative abundance of different memory T 
cell phenotypes among the transferred specific T cells did not influence the 
capacity to persist or expand in vivo (Figure 14D).
To determine whether the presence of the cognate antigen influenced the 
expansion of adoptively transferred memory T cells, we studied CMV-specific T 
cells in the PB of CMV+/+donor/recipient pairs. In these individuals, CMV-specific T 
cells were detectable in the post-transplant period and were of donor origin, as 
indicated by analysis of the mismatched HLA-A*02 (Figure 15A,B). FACS-sorting 
of these cells followed by sequencing of TCRB gene rearrangements revealed that 
some CDR3 sequences overlapped between donors and recipients in most cases 
at the amino acid (Figure 15C,D) and nucleotide level (data not shown), although 
the majority appeared to be unique. Overall, these data indicate that adoptively- 
transferred memory T cells may survive pt-Cy but expand in the recipient only in 
the presence of their cognate antigen.
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Figure 13: Phenotype and localization of antigen-specific CD4+ and CD8+ T cells. (A)
CD45RO, CCR7, CD95 and Ki-67 expression in CD8+ T cells specific for Flu IK9 and Flu GL9, 
and in CD3+ NKT cells binding the CD1d/PBS57 tetramer complex. Antigen-specific T cells are 
depicted as red dots overlaid on total CD8+ T cells (grey background). (B) CD45RO, CCR7 and 
CD95 expression by CMV-specific CD4+ and CD8+ T cells as identified in Figure 14B. Blue dots 
are the T cells producing IFN y following stimulation in vitro with the CMV pp65 peptide pool. (C) 
Frequency of antigen-specific CD8+ T and CD3+ NKT cells in bone marrow (BM) and peripheral 
blood (PB) of donors (n=13). n.s.= not significant; Wilcoxon test.
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Figure 14: Adoptively-transferred memory T cells do not expand in the absence of 
cognate antigen. (A) MHC class I tetramer identification of CD8+ T cells specific for Flu IK9 
and Flu GL9 epitopes in the PB of marrow donors (D) and the related recipients (R) at d90 post- 
haploBMT. (B) TNF and IFN y production by CD4+ and CD8+ T cells from haploBMT #10 D/R 
pair (CMV+ and CMV", respectively) following in vitro stimulation with the CMV pp65 peptide 
pool. In both A and B, numbers indicate the percentage of cells identified by the gates. (C) 
Summary of the frequency of CD3+ NKT cells binding CD1d/PBS57 tetramer, and Flu and CMV- 
specific CD4+ and CD8+ T cells from the PB of D and the related R at d45 and d90 post- 
haploBMT. *=P<0.05, Mann-Whitney test. (D) Differentiation phenotypes of the antigen-specific 
T cells identified in C. Data are presented relative to total memory T cells.
57
a) 1
0
1
CL
•  CD4
•  CD8
■2
■3
D Rd45Rd90
B
R pre-BMT R d61
IFN-g
BMT #7 BMT #13
TRBV CDR3 TRBJ
11-2 CASSLQGSGLAPRETQY 2-5
20-1 CSASLSDRGLGNTIY 1-3
19 CAST GGAATSYNEQF 2-1
19 CASTSLTSGRVNEQF 2-1
6-1 CASSEAPQIAKNIQY 2-4
6-1 CASSAPDAGRLYEQY 2-7
5-4 CASSSTSASSYNEQF 2-1
a 7-9 CASSLSASGSNEQF 2-1
10-2 CASSAPNQGNTEAF 1-1
30 CAWSVLSTSTDTQY 2-3
20-1 CSASGGMSTNEQF 2-1
29-1 CSANAGTGGNEQY 2-7
6-1 CASKAISNQPQH 1-5
7-9 CASRRGNEKLF 1-4
19 CASSNGLYGYT 1-2
19 CASSSGLYGYT 1-2
TRBV CDR3 TRBJ
6-1 CASSEGGGAGTVNEQF 2-1
7-2 CASSLTPSGSGADTQY 2-3
6-2 CASAGSGTLSYNEQF 2-1
29-1 CSVGAKWKRESGEQF 2-1
6-1 CASSERGGASNQPQH 1-5
20-1 CSASLSGRGGGNTIY 1-3
12-3 CASSRPGQGYNEQF 2-1
u. 2 CASSPSEAGRNTIY 1-3
20-1 CSAGGTSGSLGEQY 2-7
7-9 CASSAPGQGKYEQY 2-7
7-9 CASSWDREVHEQY 2-7
7-9 CASSKGEEYGYT 1-2
20-1 CSVQRGGTDTQY 2-3
20-1 CSARRDSPYEQY 2-7
BMT #27
TRBV CDR3 TRBJ
27 CATSSWTGGANSNQPQH 1-5
19 CASSSQAAQAYNEQF 2-1
12-3/12-4 CASSLLDRAPYNEQF 2-1
b h h i CASSLGGGTFTDTQY 2-3
27 CASSISRDTYNEQF 2-1
O 20-1 CSAPPPT GANSPLH 1-6
2D-1 CSARDDRANFYGYT 1-2
19 CASSWPGQGITEAF 1-1
7-9 CASSSPGQGLTEAF 1-1
2 CASEQVTWITDTQY 2-3
6-1 CASRTGATNEKLF 1-4
2 CASSLGEADTQY 2-3
TRBV CDR3 TRBJ
6-5 CASSYGTGGSGSYNEQF 2-1
6-6 CASSYSGRGQETQY 2-5
20-1 CSASPRGGQKDDT 1-2
20-1 CSARHREGTKDDT 1-2
. 7-2 CASSFSFSNTEAF 1-1
2 CASSLRQKDSPLH 1 6
2 CASSLGQKDSPLH 1 6
6-216-3 CASSYVQNTEAF 1-1
2 CASRREGQEQF 2-1
12-3/12-4 CASSYQETQY 2-5
12-3/12-4 CASSSQETQY 2-5
TRBV CDR3 TRBJ
6-216-3 CASS YLKGGGQET QY 2-5
30 CAWSSTGHNNSPLH 1 6
20-1 CSAREGQGTKNIQY 2-4
19 CASSTRGIYNSPLH 1 6
11-3 CASSLEAGPDITQY 2-3
7-9 CASSQRGTGGETQY 2-5
7-7 CASSLSGGQQETQY 2-5
7-7 CASSLERTGQETQY 2-5
30 CAWRGTGNNSPLH 1 6
12-3/12-4 CASSFDSRDSPLH 1 6
11-2 CASSSQAIYYGYT 1-2
7-2 CASSLSFSNTEAF 1-1
■ ■ ■ CASSFSFSNTEAF 1-1
30 CAWRDRYNSPLH 1 6
30 CAWAGHYNSPLH 1 6
30 CAWSERSDQPQH 1-5
30 CAWTRGFNTEAF 1-1
30 CAWITGYNTEAF 1-1
7-7 CASSTDRTDTQY 2-3
7-7 CASSLDSYNEQF 2-1
6-5 CASLKGRVGGYT 1-2
2 CASRRGVYYGYT 1-2
12-3/12-4 CASSLREETQY 2-5
7 6 CASGTGGNTQY 2-3
6 6 CASSYAGTEAF 1-1
30 CAWGSYNEQF 2-1
30 CAWSGQTEAF 1-1
12-3/12-4 CASSFQETQY 2-5
TRBV CDR3 TRBJ
6-1 CASRGGGVAGRAVYEQY 2-7
7-9 CASSRGLAGGRTDTQY 2-3
7-9 CASSLGLAGGRTDTQY 2-3
5-1 C ASSPKQGLGLTY GYT 1-2
7-2 ...  ' “ 2-3
m 20-1 CSARDDRANFYGYT 1-2
iv 27 CASSISRDTYNEQF 2-1
27 CASSISRDTYKEQF 2-1
12-3/12-4 CASTRPGQGKNEQF 2-1
7-2 CASSSEGATGREQY 2-7
7-2 CASSLEGGRKPQH 1-5
6-1 CASSTGSTNTEAF 1-1
21-1 CASSKVQVDEQF 2-1
BMT #26
TRBV CDR3 TRBJ
12-1 CASSTRDRGEDTQY 2-5
7-9 CASSSELSSQETQY 2-5
7-9 CASSLELSSQETQY 2-5
7-9 CASSLELSSQGT QY 2-5
6-5 CASKIGQAPNSPLH 1 6
a 6-2/53 CASSYGTGGNSPLH 16
10-1
7-9
7-9
CASSPGLEDNEQF
CASSWDRGVHEQY
2-1
2-7
2-7
7 6 CASSLEETGIEAF 1-1
5 5 CASSYSQGGSGYT 1-2
5 5 CASKPGQGGIGYT 1-2
TRBV CDR3 TRBJ
5 2 /5 3 CASSYSSHVGQGFSPLH 1 6
27 CASSLEAPPGGSNQPQH 1-5
7-9 CASSLDT GAASSGNT1Y 1-3
19 CASSSRDGPGDQPQH 1-5
5■o
4-1 CASSQDGPGGFDTQY 2-3
7-9 CASSLELSSQETQY 2-5
a. 5 5 CASRQTDRGFAEAF 1-1
52/53 CASSYGTGGNSPLH 16
7-9 CASSWDREVHEQY 2-7
7 6 CASSLEESGHGYT 1-2
5 6 CASSFPGEAYEQY 2-7
12-3/12-4 CASSLGTRPQH 1 6
BMT #7 BMT #13
30
6-6
CAWSVRGGLKQPQH
CASRFRAPSNQPQH
CASSESVAGVQPQH
CASSERSYGGDTQY
CASSRTGLNTEAF
7-9
30
11-2
5-5
7-8
CDR3
CDR3
CASSLRQGANTGELF
CAWSVRGGLKQPQH
CASSSGRENTEAF
CASSLRETYEQY
CASSSNYQPQH
2-2
1-5 
1-1
2-7
27
20-1
7-9
7-3
6-5
6-5
6-5
CDR3
CASSLTWTGDRNEQF
CSAPRTSGMPWDEQF
CASSWLAGGPDTQY
CASSLGIGGRTEAF
CASSISTGTAYGYT
CAGSISTGTAYGYT
CASSGVSRNTEAF
CDR3
CASSISTGTAYGYT 
CASSIST GAAYGYT 
CASSISTATAYGYT
2-1
2-1
2-3
1-2
1-2
1-2
Figure 15: TCRB clonotypic analysis of circulating CMV-specific T cells in CMV+/+ 
donor/recipient pairs. (A) Frequency of CMV-specific memory T cells in haploBMT patients 
and related donors. (B) Representative analysis of donor-derived CMV-specific T cell responses 
detected by simultaneous analysis of the mismatched HLA (in this case the donor was HLA- 
A*02~) and intracellular IFN y following stimulation with CMV pp65 overlapping peptide mix.
Plots show Aqua~CD3+ cells. (C, D) Clonal composition of CMV-specific CD4+ (C) and CD8+ (D) 
T cells in CMV+/+donor/recipient pairs. Overlapping sequences are highlighted by colors. D: 
donor; R: recipient; d, day after haploBMT.
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4.2.6 Persistence and memory differentiation of adoptively- 
transferred Tn
Next, we analyzed whether donor Tn that survived pt-Cy contribute to 
reconstitution at the antigen-specific level. We followed the fate of self/tumor- 
specific T cells by using MHC class I tetramers. The staining specificity for MART-1 
and WT-1 is shown in Figure 16A. Two CMV+ patients receiving a haploidentical 
graft from C M V  donors were able to mount CMV-specific CD8+ T cell responses 
(Figure 16B), suggesting that activation and depletion of CMV-specific T cells does 
not occur within 4 days post haploBMT. These CMV-specific responses are thought 
to originate from the transferred TN and not from pre-existing memory cells, as 
CD8+ T cells, differently from CD4+ T cells177, were shown to lack pathogen-specific 
memory T cells in unexposed individuals178.
T n specific for self-tumor epitopes, including MART-1 and WT1, behaved 
similarly. These specific cells are present at relatively high frequencies in PB and 
BM of healthy individuals (as demonstrated for MART-1 specific cells in Figure 
13C) and can thus be detected by MHC class I tetramers179,180 (Figure 16A). CD8+ 
T cells specific for MART-1 and WT1 mostly displayed a TN-phenotype in healthy 
donors (Figure 16C,E) and were able to persist up to d90 post-BMT (Figure 16D). 
These cells converted to a CD45RO+CCR7"CD95+ phenotype (as soon as d45 
post-haploBMT for MART-1), thus suggesting effector/memory differentiation 
(Figure 16C,E). On the basis of these data, we conclude that antigen-specific Tn 
survive pt-Cy and contribute to immune reconstitution in the lymphopenic host.
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Figure 16: Persistence and memory differentiation of adoptively-transferred TN. (A)
Specificity of tetramer staining in the CD8+ and CD8~ T cell fractions from healthy HLA-A*02+ 
donors. Note that some cells stain positive for two tetramers and are thus excluded from the 
analysis. (B) Frequency of CD8+ T cells in PBMCs from two CMV- donors and matched CMV+ 
recipients at different time points post-haploBMT. (C) Frequency and phenotype of MART-1 (red 
dots) and WT1 (blue dots)-specific CD8+ T cells identified by MHC class I tetramers. Numbers 
indicate the percentage of cells in each gate. Tetramer+ T cells are overlaid on top of total CD8+ 
T cell populations depicted in grey. In B and C, numbers indicate the percentage of cells 
identified by the gates. (D) Mean±SEM frequency of the cells identified in B. (E) Frequency of 
MART-1+ and WT1+ CD8+ T cells with a TN-phenotype in Ds and Rs at different time points 
post-haploBMT. *=P<0.05, Mann-Whitney test.
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4.3 B cell reconstitution after transplantation
4.3.1 B cell recovery after haploBMT is donor-dependent
Ten consecutive patients who underwent haploBMT were followed for a
median duration of 24 weeks (range: 4-26 weeks) to study the dynamics of B cell 
reconstitution. Recovery of B cells, defined as CD3~CD14"CD19+CD20+, was 
assessed by flow cytometry analysis at different time intervals after haploBMT 
according to the scheme provided in the section “Sample collection” (Figure 2).
B cells could not be detected within the first 4 weeks after haploBMT (data not 
shown), but started to appear at week 4 or 5 subsequent to the transplant (Figure 
17A). At these time points, the absolute counts of PB B cells in the recipients was 
always <2 cells/pL, a number significantly lower compared to that of the marrow 
donors. Despite the high variability observed among the patients at the investigated 
time points, the B cell count tended to increase over time starting from week 7 post 
haploBMT and, in some patients, reached levels similar to that of the healthy 
donors (Figure 17A). From week 9, we did not detect any significant difference in 
the B cell absolute count between the transplanted patients and the healthy donors 
(Figure 17A).
As showed in Figure 5, the donor-recipient chimerism analysis of PB 
leukocytes and of sorted CD3"CD56"CD14”CD19+ circulating B lymphocytes, 
revealed that almost all the B cells detected in the recipients derived from the 
marrow donors (Figure 5). Flow cytometry analysis able to identify HLA haplotypes 
on CD20+ B cells confirmed the donor origin of the reconstituting PB B cells (Figure 
17B).
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Figure 17: B cell recovery after haploBMT is donor-dependent. (A) Absolute numbers 
(cells/pL) of circulating CD20+ B lymphocytes in transplanted patients at different time points 
after haploBMT compared to those of related BM donors (D). Single donor/recipient pairs are 
identified by different symbols, as depicted in the legend. Grey box indicates the range of 
peripheral B cells observed in healthy donors. Asterisks indicate the statistical significant 
differences between BM recipients and donors, while hash-marks indicate those in the 
recipients between a given time point and week 4 post haploBMT (*, # = P<0.05; **, ## = 
P<0.01); Wilcoxon test (B) Representative flow cytometry dot plot graphs showing the 
percentage of expression of HLA-A*02 on circulating B cells in an HLA-A*02" BM donor and in 
the related HLA-A*02+ BM recipient before and 14 weeks after haploBMT. Similar data were 
obtained from two additional patients.
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4.3.2 Reconstituting PB B cells do not proliferate and retain an 
immature/transitional phenotype in the first weeks after 
haploBMT
Given that B cells are physiologically present in the BM, that the haploBMT 
protocol under investigation is based on the infusion of an unmanipulated BM3 and 
that B cells detected in the recipients derived from the marrow donors, we 
hypothesized that mature naive and memory B cells could be adoptively 
transferred with the graft and thus provide an early source of adaptive immunity in 
the host. We also reasoned that if B cells are able to persist, they would display a 
phenotype similar to those found in the BM. However, B cells were barely 
detectable in the circulation during the first 4 weeks post haploBMT and remained 
low in absolute counts and relative percentages (as compared to total lymphocytes) 
until week 8 (Figure 17A and Figure 18A). These data suggest that transferred 
donor B cells cannot persist in the host.
To determine the phenotypic properties of the recovering B cells, we analyzed 
the maturation stage of the same cells by using a polychromatic flow cytometric 
approach able to simultaneously detect multiple B cell differentiation markers. At 
weeks 5 and 8 after transplant, the vast majority of PB B cells displayed a 
CD38bnghtCD10+ immature or “transitional” phenotype, whereas the largest fraction 
of BM-derived B cells showed a CD38dimCD10~ mature phenotype (Figure 18B). 
Indeed, only a small proportion of CD38bnghtCD10+ transitional B cells could be 
detected in the donor BM (Figure 18B). To exclude the possibility that the BM- 
derived CD38bnghtCD10+ B cell subset survived post-transplant Cy infusion and 
underwent homeostatic proliferation in the post-transplant lymphopenic 
environment181, we evaluated the expression of the proliferation marker Ki-67. 
Figure 18C shows that transitional B cells at the time of immune recovery (week 8)
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were mostly negative for Ki-67 and their rate of proliferation, albeit a little increased, 
was similar to that observed in PB CD38bn9htCD10+ B cells of the donor.
On the basis of these data, we conclude that no mature B cells survive in the 
host with the infusion of an unmanipulated BM followed by pt-Cy. Rather, we 
hypothesize that B cell recovery depends on a new maturation process starting 
from haematopoietic stem cells/B cell precursors transferred with the BM.
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Figure 18: Reconstituting PB B cells do not proliferate and retain an 
immature/transitional phenotype in the first weeks after haploBMT. (A) Flow cytometry 
contour graphs showing the frequencies of CD20+ B cells in the BM of a representative donor 
and in the PB of the related recipient early post-BMT (week 5) and at recovery of the B cell 
compartment (week 8). B lymphocyte recovery is achieved when the B cell count reaches ^ 50 
cells/pL. (B) Flow cytometry contour graphs showing the percentage of circulating transitional 
(CD38br'9htCD10+) and mature (CD38 imCD10") CD20+ B cells from a representative BM donor 
and the related recipient at weeks 5, 8 and 14 after haploBMT. (C ) Flow cytometry dot plot 
graphs showing the percentage of circulating CD20+CD38br'ghtCD10+ transitional B cell 
expressing Ki-67 in the PB of a representative BM donor and the related recipient. The absolute 
number of B cells/pL is indicated in brackets (not available (N/A) for the BM of the donor and not 
detectable (N/D) in the PB of the recipient at 5 weeks after the transplant (A).
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4.3.3 B cell recovery in haploBMT recapitulates B cell
ontogeny: transitional B cells precede mature B cell 
appearance
We next analyzed the kinetics of maturation of circulating B cells. As reported 
in Figure 18B, shortly after haploBMT (week 5), almost all B cells displayed a 
CD38bn9htCD10+ transitional phenotype, while those in the PB of the donors were 
mostly mature (median of mature B cells: 3.4% and 92%, respectively; Figure 19A). 
Starting from week 9, the proportion of CD38bn9htCD10+ transitional B cells 
progressively decreased (not shown) in favour of an increased proportion of 
CD38dimCD10" mature B cells (Figure 18B, Figure 19A). To further evaluate the 
differentiation status of mature B cells, we included markers of naivety (IgM and 
IgD) and memory (IgG) in our polychromatic flow cytometry panel and used the 
gating strategy reported in Figure 4 to identify different subsets of circulating naive 
(!gM+ and/or lgD+) and memory (lgM~lgD"lgG+and lgM"lgD~lgG~) B cells starting 
from week 9 after haploBMT, when a sufficient proportion of mature B cells were 
available for analysis. The vast majority of these cells showed a naTve phenotype 
for at least 26 weeks after haploBMT (Figure 19B), while only a small proportion of 
memory B cells (lgG+ as well as IgG") were present (Figure 19C). Altogether, these 
data confirm that B cell recovery depends on a new maturation process starting 
from B cell precursors transferred with the BM.
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Figure 19: B cell recovery in haploBMT recapitulates B cell ontogeny: transitional B 
cells precede mature B cell appearance. (A) Percentage of CD38dimCD10~ mature B cells in 
the PB of BM donors and related recipients at different time points after haploBMT. Single 
donor/recipient pairs are identified by different symbols, as depicted in the legend. Asterisks 
indicate the statistical significant differences between BM recipients and donors (* = P<0.05); 
Wilcoxon test. (B) Percentage of naive circulating B cells in BM donors (D) and patients at 
different time points from week 9 after haploBMT. (C) Percentage of memory lgG+ (left graph) 
and memory IgG" (right graph) circulating B cells at different time points from week 9 after 
haploBMT. Data are depicted as in (A).
4.3.4 Maturation of transitional B cells in haploBMT requires 4 
steps of differentiation
To further investigate the steps of B cell maturation during immune recovery,
we analyzed the expression of CD5, a regulator of B cell activation, and CD21, a 
component of the B cell co-receptor complex, on transitional B cells. These surface 
markers have been proposed to characterize different stages of CD38bnghtCD10+ 
transitional B cell development131,132. Similarly to previously reported phenotypic 
distributions, we observed 3 distinct transitional PB B cell subsets during the 
course of immune reconstitution following haploBMT: T1 (CD5+CD21~), T2
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(CD5+CD21+) and the CD5"CD21+ subset (Figure 20A). In addition, we report an 
additional stage, here named TO, which is characterized by the absence of CD5 
and CD21 and seems to precede the aforementioned T1 and T2 during B cell 
recovery.
The distribution of patients’ transitional B cells among the differentiation 
stages shortly after BMT was largely different to that present in the PB of the 
related marrow donors and changed significantly over time. At week 5, transitional 
B cells mostly displayed a TO and, in smaller proportion, a T1 phenotype 
(mean±SEM: 59.4±8.4 and 31.6±7.6, respectively). At week 8, the frequency of TO 
cells started to decrease (mean±SEM: 29.7±9.6), whereas the T1 cell subset 
represented the dominant population (mean±SEM: 41.6±4.1). At later time points 
(e.g., week 14), the majority of the transitional B cells became CD21+, either being 
T2 or CD5“CD21+ phenotype cells (mean±SEM: 38.2±11.9 and 21.8±11.6, 
respectively). The relative distribution of transitional B cell subpopulations at week 
14 after haploBMT was similar to that observed in the PB of the related BM donors 
and showed the following percentages: 14.4±3.9 for TO, 25.4±11.6 for T1,
38.2±11.9 for T2 and 21.8±11.6 for CD5"CD21+ (Figure 20A).
To verify that the transitional B cell subsets in patients receiving haploBMTs 
undergo a maturation process leading to the generation of mature naive B cells, we 
analyzed the expression of IgD, IgM and CD21 overtime. The expression of these 
surface markers is associated with the acquisition of a fully mature naTve B cell 
phenotype132. Our results show that the levels of CD21, IgD and IgM on transitional 
B cells increased over time following haploBMT (Figure 20B,C). Of note, the 
surface expression of IgM at week 15 was significantly higher compared to that of 
circulating transitional B cells of the related BM donors (Figure 20B,C). These data 
indicate that, during the course of immune reconstitution following haploBMT,
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transitional B cells undergo differentiation and acquire the expression of CD21, IgM 
and IgD. At approximately 6 months (e.g., week 26) after the transplantation 
procedure, the amount of CD21, IgD and IgM on the surface of circulating B cells 
from BM recipients was similar to that of PB B cells of the related donors, thus 
suggesting that the B cells completed their maturation process.
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Figure 20: Maturation of transitional B cells in haploBMT requires 4 steps of 
differentiation. (A) Upper panel: CD5 and CD21 expression on the surface of CD38bn£,h,CD10+ 
transitional B cells from a representative BM recipient at weeks 5, 8 and 14 after haploBMT.
The expression of the same markers in the peripheral blood of a healthy donor is depicted in 
gray in the background. Lower panel: pie charts depicting the relative proportions of the 4 
subsets identified by CD5 and CD21 expression, as follows: TO (CD5XD21- ), T1 (CD5+CD21~), 
T2 (CD5+CD21+) and CD5XD21*. * = P<0.05; ** = P<0.01; *** = P<0.001; permutation test. (B) 
Flow cytometry histograms showing the expression of CD21, IgD and IgM on circulating 
CD38bnghtCD10+ transitional B cells from a representative BM recipient at weeks 5, 8,15 after 
haploBMT (open black line) and from the related donor (filled gray histogram). Dashed 
histograms indicate the expression of the same markers in CD3+ T cells, used as a negative 
reference. Numbers in the plot indicate the MFI. (C) MFI of CD21, IgD and IgM expression on 
the same cells from the BM recipients at different time points after haploBMT compared to those 
of the related BM donors (D). Single donor/recipient pairs are identified by different symbols, as 
depicted in the legend. Asterisks indicate the statistical significant differences between BM 
donors (D) and recipients (* = P<0.05); Wilcoxon test.
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5 Discussion and conclusions
Understanding the cellular mechanisms underlying immune cell reconstitution 
following BMT is critical for the development of alternative therapeutic approaches 
aimed at improving the prognosis of patients affected by hematological 
malignancies. Such studies also hold the potential to advance our knowledge of 
immune cell ontogeny in physiological human settings.
Unmanipulated haploBMT with pt-Cy has recently been introduced as an 
approach that provides a donor for nearly all patients lacking an HLA-matched 
donor and to improve immune reconstitution through the adoptive transfer of 
mature immune cells. A comprehensive analysis of immune recovery immediately 
after transplantation has never been reported in the context of this clinical 
procedure. Therefore, it is unclear how pt-Cy works as regards the transfer of 
immunity from donor to recipient. The present study informs the mechanisms of 
adaptive immune cell reconstitution and focused on T and B cell recovery. Figure 
21 summarizes the proposed mechanisms of T and B cell immune reconstitution 
that arise from this work.
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Figure 21: Proposed mechanism for immune reconstitution following haploBMT 
with non-myeloablative conditioning regimen and high-dose Cy after transplant. Donor 
BM-derived haematopoietic stem cells, lymphoid precursors, B cells, TN and T Me m  are infused in 
the recipient with the graft. Haematopoietic stem cells and lymphoid precursors survive Cy 
given at d3 and d4 after BMT and contribute to B and T cell reconstitution months after BMT, 
generating TN and Transitional B cells (BTr). Conversely, donor BM-derived B cells do not 
survive after Cy. The allogeneic antigens (allo-Ags) and expansions driven by homeostatic 
cytokines (e.g., IL-7 and IL-15), the availability of which increases after chemotherapy, induce T 
cell activation. Activated T cells start to proliferate and uniformly acquire an effector phenotype 
(HLA-DR+, Ki-67+), irrespective of their origin. Cy treatment preferentially depletes proliferating 
cells, leaving quiescent T cells. TN spared by Cy rapidly differentiate into T Sc m  a s  soon as d7 
after transplantation. In the following weeks, naive-derived TScMare able to expand in response 
to self/tumor antigens (ags) or homeostatic expansion, thus generating T Me m - On the other 
hand, donor BM-derived T Me m , which have survived Cy, are limited in terms of immune 
reconstitution capacity as suggested by their lower frequency at d7 compared to T Sc m - In the 
following weeks, the T MEm  expansion is dependent on cognate-ag encounter.
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The immune reconstitution dynamics of T cells is markedly different from B 
cell recovery dynamics. Despite the fact that both B and T cells are transferred with 
the graft in the recipient, only mature T cells are detectable in the recipient after 
transplant, thus indicating that they survive pt-Cy and provide a source of T cells in 
transplanted patients (Figure 21). Conversely, B cells are not detectable in the PB, 
suggesting that they do not survive in the recipient (Figure 21).
We hypothesized that B cell recovery is the result of a de novo differentiation 
process of donor haematopoietic stem cells or lymphoid precursors (Figure 21).
The following experimental evidence supports our hypothesis. We observed that 
CD19+CD20+ B cells found in PB and bearing an immature/transitional phenotype 
(i.e., CD38bn9htCD10+) dominate the circulating B cell compartment in the BM 
recipients during the early weeks following the transplant (Figure 18). This is in line 
with previous reports analyzing the recovery of B cells following various BMT 
protocols133,142,182. Although not formally tested because of the very low number of 
mononuclear cells recovered in the early days after transplantation, pt-Cy likely 
mediates the loss of transferred B cells (Figure 18 and Figure 21). B cells are in 
fact known to harbour low levels of the aldehyde dehydrogenase responsible for Cy 
detoxification and are thus highly sensitive to the drug in vitro and in vivo183.
We took advantage of the complete depletion of B cells in transplanted 
patients to study the process of B cell differentiation. We performed a detailed 
longitudinal phenotypic analysis of markers associated with B cell differentiation. 
The B cell compartment is initially characterized by the presence of transitional B 
cells and is progressively repopulated by mature naTve B cells that acquire IgG-  
and lgG+ memory phenotypes later on. At the same time, the frequency of 
transitional B cells gradually decreases (Figure 19). Moreover, the differentiation of 
transitional B cells is characterized by a process of progressive maturation
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identified by CD5 and CD21 expression, as previously suggested by other 
reports131,132. In humans, CD5 is expressed by immature/transitional B cells and is 
down-regulated by mature naTve B cells129, while CD21 has been proposed to 
distinguish the CD21"T1 transitional stage of differentiation from the CD21+ T2 
stage131,132. T1 cells are considered precursors of T2 B cells on the basis of 
multiple phenotypic and functional aspects132.
Recently, it has been proposed that an additional subset of B cells that are 
phenotypically naYve but retain CD5 expression represents pre-naTve B cells131. 
Others referred to cells with a similar naTve phenotype and functional capacity, but 
negative for CD5, as T3 transitional B cells184. Our experimental approach allowed 
us to identify the above-mentioned T1 and T2 stages as well as a CD5~CD21+ 
transitional subpopulation. In addition, we report a new putative transitional B cell 
stage, here named TO, defined by the absence of both CD5 and CD21 (Figure 20).
Discrete transitional B cell subsets develop at different time points following 
transplantation, thus revealing new insights into the process of B cell maturation in 
the periphery. Peripheral B cell development during reconstitution begins with the 
TO (CD5~CD21~) subset and culminates with the expansion of CD5“CD21+ cells as 
well as CD38dimCD10" naTve B cells at ~6 months post haploBMT. TO cells 
represent only a small proportion of transitional B cells in the PB of healthy donors 
but constitute up to 60% of total CD19+CD20+ B cells in the patients at 5 weeks 
post haploBMT (Figure 20).
The recovery of B cells in transplanted patients suggests that B cell 
differentiation proceeds according to the relationship TO T1 -> T2 -> CD5"CD21+ 
transitional -> naTve lymphocytes. In accordance with the linear differentiation 
model that has been proposed for other lymphocyte populations, e.g. T cells75,185, 
discrete subsets of B cells lose or acquire specific functions with progressive
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differentiation. It is unclear at this time whether CD5"CD21+ transitional and T3 pre- 
naTve B cells (expressing CD5 or not) constitute the same subset on a functional 
basis or whether they are related to each other in a precursor-progeny relationship. 
It also remains to be determined whether TO cells precede the other subsets of 
transitional B cells in terms of functional capacity.
At ~6 months post haploBMT, the distribution of PB B cells among the various 
subsets of differentiation is similar to that observed for circulating B cells from the 
related BM donors. A slightly reduced proportion of lgG+ and IgG" memory cells is 
observed in transplanted patients versus controls. Patients receiving allogeneic 
transplants are routinely vaccinated for multiple pathogens starting at 6 months 
after transplantation. These vaccines would potentially induce antibody responses 
that are similar to those observed in other transplantation settings, but it is well 
documented that transplanted patients respond poorly to vaccines for multiple 
reasons, including the immature characteristics of the B cell compartment186, the 
contraction of the B and T cell repertoire and the lack of sufficient T cell help due to 
the low number of CD4+ T cells121,187.
We also report the cellular mechanisms responsible for T cell reconstitution 
following haploHSCT and pt-Cy at the antigen-specific and clonal level and suggest 
that “TN-derived TScm” play a non-redundant role in this regard. Extensive 
phenotypic and functional analysis of T cell subsets during the first few days 
following transplantation reveal that non-alloreactive TN are spared by pt-Cy 
because of their delayed activation kinetics. Unexpectedly, TN are outnumbered by 
TscM-phenotype cells at d7, which later display T scm functional properties. 
Conversely, as much as 70% of memory/effector-phenotype T cells are 
proliferating by d3 post-haploBMT and are subsequently depleted by pt-Cy (Figure 
21). Experiments performed in mouse models by Mayumi et al. showed that pt-Cy
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failed to block GVHD following transfer of allogeneic donor splenocytes. The 
transferred splenocytes were derived from mice that had been immunized with host 
T cells 7 days before28, thus leading to the hypothesis that memory T cells are 
more resistant to pt-Cy compared to TN25. However, since d7 coincides with the 
effector phase (i.e., the peak of T cell expansion), escape from pt-Cy possibly 
occurred because of the relative abundance of transferred effectors rather than the 
acquisition of memory capacity. Our experiments show that both Tn and memory T 
cells divide in response to allogeneic stimulation and that TN rapidly acquire 
CD45RO, thus indicating that the proliferating memory/effector-phenotype fraction 
observed at d3 includes T cells derived from both compartments (Figure 6).
TscM-phenotype cells are the dominant donor T cells in the PB following pt-Cy 
and are thought to derive from donor TN. A weakness of the current study is that 
this relationship could not be demonstrated directly at the antigen-specific or clonal 
level due to the low abundance of these cells in vivo. Nevertheless, the results with 
polyclonal T cell populations (experiments shown in Figure 11) support the concept 
that T n develop into Tscm cells. Although only circulating T cells could be tested for 
ethical reasons, proliferation of pre-existing donor T Scm or redistribution of Tscm 
from lymphoid tissues seem unlikely, given the depletion of proliferating cells by pt- 
Cy and the virtual absence of T scm in the BM, respectively. Moreover, IL-7 and IL- 
15, which are elevated in lymphopenic individuals, favours the generation of T Scm 
from T n precursors188. Based on this and the results from the current study, it is 
concluded that post-transplant T scm in haploHSCT derive from TN.
The acquisition of memory/effector phenotypes by self/tumor-specific T cells 
also suggests that transferred TN progress through an early T Scm stage (Figure 21). 
Self-specific memory T cells are rarely observed, unless in pathological conditions. 
For instance, MART-1-specific memory cells are abundant in metastatic melanoma
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but rare in healthy donors71,189, hence leading to the supposition that high antigen 
load, co-stimulation and local inflammation are required for MART-1-specific T cell 
priming190. Alternatively, the conversion of Tn into memory-like cells has been 
reported in mice to occur in response to lymphopenia (i.e., increased levels of 
homeostatic cytokines)191'194. Whether homeostatic proliferation rather than 
cognate antigen stimulation is the major mechanism driving the differentiation of 
self/tumor specific Tn will require further studies.
Although still present after Cy treatment, residual memory T cells, including 
T cm, display limited reconstitution capacity, at least in the circulation (Figure 14). 
The presence of cognate antigen in the post-transplant environment seems to 
dictate the expansion of antigen-specific memory T cells, as (some) transferred 
antigen-specific memory T cell clones could be detected in CMV infection-matched 
transplants (Figure 15). These data, together with those obtained from CMV-'* 
transplants, implicate that reactivation of CMV and, possibly, other persistent 
pathogens occurs late enough to allow pathogen-specific T cells to escape pt-Cy- 
mediated depletion. However, at the same time, the depletion of some non- 
alloreactive memory T cell clones by pt-Cy cannot be completely ruled out. This 
might be caused by their more rapid homeostatic proliferation (and subsequent 
apoptosis) in vitro71 and in v/Vo104 compared to TN, Whether T cell memory can 
persist in these individuals in the relative absence of cognate antigen in body sites 
other than the circulation remains an open question.
Collectively, our results shed light on the mechanisms governing pt-Cy 
function in vivo, suggesting that transferred T N may acquire T Scm traits in the 
lymphopenic environment and subsequently contribute to immune reconstitution.
At the antigen-specific level, pt-Cy allows the generation of primary and 
memory T cell responses in the presence of persistent antigen in the host.
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However, although still present, memory CD4 and CD8 T cells displayed limited 
expansion capacity in the blood of recipients.
On the basis of the reported data and evidence that the abundance of TN in 
BM correlates with improved overall survival and decreased acute GVHD195, we 
suggest that the adoptive transfer of large numbers of TN before pt-Cy may favour 
the generation of T scm and boost immune reconstitution.
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6 Abbreviations
Allo-APCs MHC-mismatched antigen-presenting cells
APCs Antigen-presenting cells
Auto-APCs Autologous antigen-presenting cells
BMT Bone marrow transplantation
BM Bone marrow
CCR CC chemokine receptor
CFSE 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester
CMV Cytomegalovirus
Cy Cyclophosphamide
d Day
DCs Dendritic cells
FK Tacrolimus
yc Gamma chain
GVHD Graft-versus-host disease
HaploBMT Haploidentical bone marrow transplantation
HaploHSCT Haploidentical haematopoietic stem sell transplantation
HLA Human leukocyte antigen
HSCT Haematopoietic stem sell transplantation
IFN Interferon
Ig Immunoglobulin
IL Interleukin
mAb Monoclonal antibody
MART-1 Melanoma antigen recognized by T cells 1
MFI Median fluorescence intensity
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MHC Major histocompatibility complex
MLR Mixed lymphocyte reaction
MMF Mycophenolate mofetil
MZ Marginal zone
NK Natural killer
NKT Natural killer T
NL NaTve-like
PB Peripheral blood
PBMCs Peripheral blood mononuclear cells
PMA Phorbol 12-myristate 13-acetate
pMHC Peptide-MHC
pt-Cy Post-transplant infusion of cyclophosphamide
RT Room temperature
SEM Standard error of the mean
T cm Central memory T cells
TCR T cell receptor
T em Effector memory T cell
T mem Memory T cells
T n NaTve T cells
T reg Regulatory T cells
T rte Recent thymic emigrant T cells
T scm T memory stem cells
T te Terminal effector memory T cells
Ttm Transitional memory T cells
WT1 Wilms’ Tumor 1
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